DaVita (DVA) 10-Q 1 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 29, 2014
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'DVA	'
Entity Registrant Name	'DAVITA HEALTHCARE PARTNERS INC.	'
Entity Central Index Key	'0000927066	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	214,800,000

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Patient service revenues	$2,187,249	$2,048,651	$4,301,347	$4,028,524
Less: Provision for uncollectible accounts	-88,052	-72,191	-171,249	-142,248
Net patient service revenues	2,099,197	1,976,460	4,130,098	3,886,276
Capitated revenues	799,369	710,074	1,586,934	1,472,689
Other revenues	273,923	185,139	498,233	342,290
Total net revenues	3,172,489	2,871,673	6,215,265	5,701,255
Operating expenses and charges:	'	'	'	'
Patient care costs and other costs	2,246,538	2,014,320	4,426,310	3,975,211
General and administrative	298,636	268,110	582,697	552,520
Depreciation and amortization	145,907	130,589	288,486	256,498
Provision for uncollectible accounts	3,208	1,260	5,719	2,138
Equity investment income	-6,095	-7,649	-13,467	-17,016
Loss contingency reserve	'	'	'	300,000
Contingent earn-out obligation adjustment	'	-56,977	'	-56,977
Total operating expenses and charges	2,688,194	2,349,653	5,289,745	5,012,374
Operating income	484,295	522,020	925,520	688,881
Debt expense	-106,132	-108,096	-212,467	-213,913
Debt refinancing charges	-97,548	'	-97,548	'
Other income (loss), net	1,693	-1,374	3,391	-776
Consolidated income from continuing operations before income taxes	282,308	412,550	618,896	474,192
Income tax expense	100,887	129,192	225,738	144,336
Income from continuing operations	181,421	283,358	393,158	329,856
Discontinued operations:	'	'	'	'
Loss from operations of discontinued operations, net of tax	'	'	'	-139
Gain on disposal of discontinued operations, net of tax	'	'	'	13,375
Net income	181,421	283,358	393,158	343,092
Less: Net income attributable to noncontrolling interests	-33,738	-28,982	-62,186	-58,552
Net income	147,683	254,376	330,972	284,540
Earnings per share:	'	'	'	'
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.70	$1.21	$1.56	$1.29
Basic net income per share attributable to DaVita HealthCare Partners Inc.	$0.70	$1.21	$1.56	$1.36
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.68	$1.18	$1.53	$1.26
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	$0.68	$1.18	$1.53	$1.33
Weighted average shares for earnings per share:	'	'	'	'
Basic	212,258,994	209,797,334	211,817,893	209,385,380
Diluted	216,720,944	214,849,164	216,420,713	214,490,452
Amounts attributable to DaVita HealthCare Partners Inc.:	'	'	'	'
Income from continuing operations	147,683	254,376	330,972	271,291
Discontinued operations	'	'	'	13,249
Net income	$147,683	$254,376	$330,972	$284,540

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net income	$181,421	$283,358	$393,158	$343,092
Unrealized losses on interest rate swap and cap agreements:	'	'	'	'
Unrealized (loss) gain on interest rate swap and cap agreements	-5,209	11,685	-7,714	9,316
Reclassifications of net swap and cap agreements realized loss into net income	4,997	3,462	8,356	5,969
Unrealized gains on investments:	'	'	'	'
Unrealized gain on investments	578	101	909	719
Reclassification of net investment realized gains into net income	'	'	-207	-94
Foreign currency translation adjustments	1,939	-1,841	1,967	-3,947
Other comprehensive income	2,305	13,407	3,311	11,963
Total comprehensive income	183,726	296,765	396,469	355,055
Less: Comprehensive income attributable to noncontrolling interests	-33,738	-28,982	-62,186	-58,552
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$149,988	$267,783	$334,283	$296,503

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$1,420,973	$946,249
Short-term investments	63,835	6,801
Accounts receivable, less allowance of $244,878 and $237,143	1,550,252	1,485,163
Inventories	99,650	88,805
Other receivables	455,620	349,090
Other current assets	164,591	176,414
Income tax receivable	6,965	10,315
Deferred income taxes	399,361	409,441
Total current assets	4,161,247	3,472,278
Property and equipment, net of accumulated depreciation of $1,936,494 and $1,778,259	2,290,844	2,189,411
Intangibles, net of accumulated amortization of $565,839 and $483,773	2,022,875	2,024,373
Equity investments	42,842	40,686
Long-term investments	87,614	79,557
Other long-term assets	66,106	79,598
Goodwill	9,254,043	9,212,974
Total assets	17,925,571	17,098,877
LIABILITIES AND EQUITY	'	'
Accounts payable	405,751	435,465
Other liabilities	465,242	464,422
Accrued compensation and benefits	626,617	603,013
Medical payables	304,551	287,452
Loss contingency reserve	397,000	397,000
Senior notes (6 3/8% Senior Notes)	291,907	'
Current portion of long-term debt	117,080	274,697
Total current liabilities	2,608,148	2,462,049
Long-term debt	8,390,578	8,141,231
Other long-term liabilities	386,033	380,337
Deferred income taxes	823,745	812,419
Total liabilities	12,208,504	11,796,036
Commitments and contingencies	'	'
Noncontrolling interests subject to put provisions	760,242	697,300
Equity:	'	'
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)	0	0
Common stock ($0.001 par value, 450,000,000 shares authorized; 214,759,091 and 213,163,248 shares issued and outstanding at June 30, 2014 and at December 31, 2013, respectively)	215	213
Additional paid-in capital	1,089,929	1,070,922
Retained earnings	3,694,961	3,363,989
Accumulated other comprehensive income (loss)	666	-2,645
Total DaVita HealthCare Partners Inc. shareholders' equity	4,785,771	4,432,479
Noncontrolling interests not subject to put provisions	171,054	173,062
Total equity	4,956,825	4,605,541
Total liabilities and equity	$17,925,571	$17,098,877

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance	$244,878	$237,143
Property and equipment, accumulated depreciation	1,936,494	1,778,259
Intangibles, accumulated amortization	$565,839	$483,773
Senior note, interest rate	6.38%	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	214,759,091	213,163,248
Common stock, shares outstanding	214,759,091	213,163,248

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOW (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income	$393,158	$343,092
Adjustments to reconcile net income to cash provided by operating activities:	'	'
Loss contingency reserve	'	300,000
Depreciation and amortization	288,470	256,382
Debt refinancing charges	97,548	'
Stock-based compensation expense	29,699	32,266
Tax benefits from stock award exercises	42,110	36,524
Excess tax benefits from stock award exercises	-30,238	-28,442
Deferred income taxes	13,826	-102,039
Equity investment income, net	2,257	-496
Other non-cash (income) charges and loss on disposal of assets	22,861	-69,050
Changes in operating assets and liabilities, other than from acquisitions and divestitures:	'	'
Accounts receivable	-65,079	-17,829
Inventories	-10,731	924
Other receivables and other current assets	-95,580	-65,349
Other long-term assets	2,158	-1,220
Accounts payable	-46,022	-94,894
Accrued compensation and benefits	19,912	-14,279
Other current liabilities	31,970	82,905
Income taxes	2,886	-9,182
Other long-term liabilities	-17,707	36,713
Net cash provided by operating activities	681,498	686,026
Cash flows from investing activities:	'	'
Additions of property and equipment, net	-278,593	-258,396
Acquisitions	-98,442	-152,112
Proceeds from asset and business sales	215	64,363
Purchase of investments available for sale	-6,117	-3,286
Purchase of investments held-to-maturity	-121,333	-1,032
Proceeds from sale of investments available for sale	1,277	1,091
Proceeds from sale of investments held to maturity	64,561	1,376
Purchase of intangible assets and equity investment	-4,760	-7
Distributions received on equity investments	337	116
Net cash provided by (used in) investing activities	-442,855	-347,887
Cash flows from financing activities:	'	'
Borrowings	33,136,743	33,445,567
Payments on long-term debt and other financing costs	-32,788,307	-33,696,216
Deferred financing costs and debt redemption costs	-106,937	-716
Distributions to noncontrolling interests	-65,818	-65,206
Stock award exercises and other share issuances, net	7,274	8,819
Excess tax benefits from stock award exercises	30,238	28,442
Contributions from noncontrolling interests	28,265	20,132
Proceeds from sales of additional noncontrolling interests	933	5,903
Purchases from noncontrolling interests	-5,743	-474
Net cash provided by (used in) financing activities	236,648	-253,749
Effect of exchange rate changes on cash and cash equivalents	-567	-234
Net increase in cash and cash equivalents	474,724	84,156
Cash and cash equivalents at beginning of period	946,249	533,748
Cash and cash equivalents at end of period	$1,420,973	$617,904

CONSOLIDATED_STATEMENTS_OF_EQU

CONSOLIDATED STATEMENTS OF EQUITY (USD $)	Total	Non- controlling interests subject to put provisions	Common stock	Additional paid-in capital	Retained earnings	Treasury stock	Accumulated other comprehensive income (loss)	Total	Non- controlling interests not subject to put provisions
In Thousands, except Share data, unless otherwise specified
Beginning Balance at Dec. 31, 2012	'	$580,692	$270	$1,208,665	$3,731,835	($1,162,336)	($15,297)	$3,763,137	$153,788
Beginning Balance (in shares) at Dec. 31, 2012	'	'	269,725,000	'	'	-58,728,000	'	'	'
Comprehensive income:	'	'	'	'	'	'	'	'	'
Net income	'	78,215	'	'	633,446	'	'	633,446	45,540
Other comprehensive income	'	'	'	'	'	'	12,652	12,652	'
Stock purchase shares issued (in shares)	'	'	238,000	'	'	'	'	'	'
Stock purchase shares issued	'	'	'	12,817	'	'	'	12,817	'
Stock unit shares issued (in shares)	'	'	7,000	'	'	164,000	'	'	'
Stock unit shares issued	'	'	'	-3,286	'	3,247	'	-39	'
Stock-settled SAR shares issued (in shares)	'	'	313,000	'	'	1,444,000	'	'	'
Stock-settled SAR shares issued	'	'	'	-29,025	'	28,561	'	-464	'
Stock-based compensation expense	'	'	'	59,998	'	'	'	59,998	'
Excess tax benefits from stock awards exercised	'	'	'	36,197	'	'	'	36,197	'
Distributions to noncontrolling interests	'	-80,353	'	'	'	'	'	'	-58,973
Contributions from noncontrolling interests	'	22,053	'	'	'	'	'	'	14,943
Sales and assumptions of additional noncontrolling interests	'	23,642	'	-1,442	'	'	'	-1,442	10,770
Purchases from noncontrolling interests	'	-512	'	-3,119	'	'	'	-3,119	-147
Expiration of put option and other reclassification	'	-7,141	'	'	'	'	'	'	7,141
Changes in fair value of noncontrolling interests	'	80,704	'	-80,704	'	'	'	-80,704	'
Treasury stock retirement (Shares)	'	'	'	'	'	57,120,000	'	'	'
Treasury stock retirement	'	'	-57	-129,179	-1,001,292	1,130,528	'	'	'
Ending Balance at Dec. 31, 2013	4,605,541	697,300	213	1,070,922	3,363,989	'	-2,645	4,432,479	173,062
Ending Balance (in shares) at Dec. 31, 2013	213,163,248	'	213,163,000	'	'	'	'	'	'
Comprehensive income:	'	'	'	'	'	'	'	'	'
Net income	393,158	43,590	'	'	330,972	'	'	330,972	18,596
Other comprehensive income	3,311	'	'	'	'	'	3,311	3,311	'
Stock unit shares issued (in shares)	'	'	290,000	'	'	'	'	'	'
Stock unit shares issued	'	'	'	-27	'	'	'	-27	'
Stock-settled SAR shares issued (in shares)	'	'	1,306,000	'	'	'	'	'	'
Stock-settled SAR shares issued	'	'	2	-2	'	'	'	'	'
Stock-based compensation expense	'	'	'	29,699	'	'	'	29,699	'
Excess tax benefits from stock awards exercised	'	'	'	30,238	'	'	'	30,238	'
Distributions to noncontrolling interests	'	-41,733	'	'	'	'	'	'	-24,085
Contributions from noncontrolling interests	'	18,240	'	'	'	'	'	'	10,025
Sales and assumptions of additional noncontrolling interests	'	918	'	15	'	'	'	15	'
Purchase and gains from noncontrolling interests	'	-446	'	1,247	'	'	'	1,247	-6,544
Adjustment in ownership interests	'	'	'	210	'	'	'	210	'
Changes in fair value of noncontrolling interests	'	42,373	'	-42,373	'	'	'	-42,373	'
Ending Balance at Jun. 30, 2014	$4,956,825	$760,242	$215	$1,089,929	$3,694,961	'	$666	$4,785,771	$171,054
Ending Balance (in shares) at Jun. 30, 2014	214,759,091	'	214,759,000	'	'	'	'	'	'

Condensed_consolidated_interim

Condensed consolidated interim financial statements	6 Months Ended
	Jun. 30, 2014
Condensed consolidated interim financial statements	'
	1. Condensed consolidated interim financial statements
	The condensed consolidated interim financial statements included in this report are prepared by the Company without audit. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve the accrual of an estimated loss contingency reserve and its impact on the Company’s income taxes, revenue recognition and accounts receivable, impairments of long-lived assets, fair value estimates, accounting for income taxes, variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, long-term incentive program compensation and medical liability claims. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of the operating results for the full year. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Prior year balances and amounts have been reclassified to conform to the current year presentation. The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and has included all necessary disclosures.

Earnings_per_share

Earnings per share	6 Months Ended
	Jun. 30, 2014
Earnings per share	'
	2. Earnings per share
	Basic net income per share is calculated by dividing net income attributable to the Company, adjusted for any change in noncontrolling interests redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units (under the treasury stock method).
	The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows:
			Three months ended						Six months ended
			June 30,						June 30,
			2014			2013			2014			2013
	Basic:
	Income from continuing operations attributable to DaVita HealthCare Partners Inc.		$	147,683		$	254,376		$	330,972		$	271,291
	Increase in noncontrolling interests redemption rights in excess of fair value			—			(259	)		—			(259	)
	Income from continuing operations for basic earnings per share calculation		$	147,683		$	254,117		$	330,972		$	271,032
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			—			—			13,249
	Net income attributable to DaVita HealthCare Partners Inc. for basic earnings per share calculation		$	147,683		$	254,117		$	330,972		$	284,281
	Weighted average shares outstanding during the period			214,451			211,986			214,010			211,574
	Vested stock units			2			5			2			5
	Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger			(2,194	)		(2,194	)		(2,194	)		(2,194	)
	Weighted average shares for basic earnings per share calculation			212,259			209,797			211,818			209,385
	Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.		$	0.7		$	1.21		$	1.56		$	1.29
	Basic income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.		$	—		$	—		$	—		$	0.07
	Basic net income per share attributable to DaVita HealthCare Partners Inc.		$	0.7		$	1.21		$	1.56		$	1.36
	Diluted:
	Income from continuing operations attributable to DaVita HealthCare Partners Inc.		$	147,683		$	254,376		$	330,972		$	271,291
	Increase in noncontrolling interests redemption rights in excess of fair value			—			(259	)		—			(259	)
	Income from continuing operations for diluted earnings per share calculation		$	147,683		$	254,117		$	330,972		$	271,032
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			—			—			13,249
	Net income attributable to DaVita HealthCare Partners Inc. for diluted earnings per share calculation		$	147,683		$	254,117		$	330,972		$	284,281
	Weighted average shares outstanding during the period			214,451			211,986			214,010			211,574
	Vested stock units			2			5			2			5
	Assumed incremental shares from stock plans			2,268			2,858			2,409			2,911
	Weighted average shares for diluted earnings per share calculation			216,721			214,849			216,421			214,490
	Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.		$	0.68		$	1.18		$	1.53		$	1.26
	Diluted income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.		$	—		$	—		$	—		$	0.07
	Diluted net income per share attributable to DaVita HealthCare Partners Inc.		$	0.68		$	1.18		$	1.53		$	1.33
	Anti-dilutive stock-settled awards excluded from calculation(1)			990			4,520			1,995			3,353
	(1)	Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts_receivable

Accounts receivable	6 Months Ended
	Jun. 30, 2014
Accounts receivable	'
	3. Accounts receivable
	Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of the Company’s accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by government payors, like Medicare, the Company receives 80% of the payment directly from Medicare as established under the government’s bundled payment system, in the case of dialysis services receivables, and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company’s estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. Approximately 1% of the Company’s net accounts receivable are associated with patient pay and it is the Company’s policy to record an allowance for 100% of these outstanding dialysis accounts receivable balances when those amounts due are outstanding for more than four months.
	During the six months ended June 30, 2014, the Company’s allowance for doubtful accounts increased by approximately $7,735. This was mainly due to an increase relating to the U.S. dialysis and related lab services, primarily as a result of additional non-covered Medicare write-offs. There were no unusual transactions impacting the allowance for doubtful accounts.

Investments_in_debt_and_equity

Investments in debt and equity securities and other investments	6 Months Ended
	Jun. 30, 2014
Investments in debt and equity securities and other investments	'
	4. Investments in debt and equity securities and other investments
	Based on the Company’s intentions and strategy concerning investments in debt securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values, including those of mutual funds, common stock and other debt securities, are classified as available-for-sale and recorded at fair value.
	The Company’s investments in securities consist of the following:
		June 30, 2014						December 31, 2013
		Held to		Available		Total		Held to		Available		Total
		maturity		for sale				maturity		for sale
	Certificates of deposit and money market funds due within one year	$	62,374	$	—	$	62,374	$	5,601	$	—	$	5,601
	Investments in mutual funds and common stock		—		25,685		25,685		—		19,421		19,421
		$	62,374	$	25,685	$	88,059	$	5,601	$	19,421	$	25,022
	Short-term investments	$	62,374	$	1,461	$	63,835	$	5,601	$	1,200	$	6,801
	Long-term investments		—		24,224		24,224		—		18,221		18,221
		$	62,374	$	25,685	$	88,059	$	5,601	$	19,421	$	25,022
	The cost of the certificates of deposit and money market funds at June 30, 2014 and December 31, 2013 approximates their fair value. As of June 30, 2014 and December 31, 2013, the available-for-sale investments included $6,161 and $5,096 of gross pre-tax unrealized gains, respectively. During the six months ended June 30, 2014, the Company recorded gross pre-tax unrealized gains of $1,405, or $909 after tax, in other comprehensive income associated with changes in the fair value of these investments. During the six months ended June 30, 2014, the Company sold investments in mutual funds for net proceeds of $1,277 and recognized a pre-tax gain of $340, or $207 after-tax, which was previously recorded in other comprehensive income. During the six months ended June 30, 2013, the Company sold investments in mutual funds for net proceeds of $1,091 and recognized a pre-tax gain of $155, or $94 after-tax, which was previously recorded in other comprehensive income.
	The investments in mutual funds classified as available-for-sale are held within a trust to fund existing obligations associated with several of the Company’s non-qualified deferred compensation plans.
	As of June 30, 2014, the Company held $5,000 of preferred stock in a privately held company that is accounted for under the cost method as this investment does not have a readily determinable fair value.
	Certain HCP entities are required to maintain minimum cash balances in order to comply with regulatory requirements in conjunction with medical claim reserves. As of June 30, 2014, this minimum cash balance was approximately $58,000.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2014
Goodwill	'
	5. Goodwill
	Changes in goodwill by reportable segments were as follows:
		Six months ended June 30, 2014
		U.S. dialysis and			HCP			Other-ancillary			Consolidated total
		related lab services						services and
								strategic initiatives
	Balance at December 31, 2013	$	5,469,473		$	3,516,162		$	227,339		$	9,212,974
	Acquisitions		2,915			38,639			820			42,374
	Other adjustments		—			(2,277	)		972			(1,305	)
	Balance at June 30, 2014	$	5,472,388		$	3,552,524		$	229,131		$	9,254,043
		Year ended December 31, 2013
		U.S. dialysis and			HCP			Other-ancillary			Consolidated total
		related lab services						services and
								strategic initiatives
	Balance at December 31, 2012	$	5,309,152		$	3,506,571		$	137,027		$	8,952,750
	Acquisitions		163,037			17,833			90,397			271,267
	Divestitures		(2,728	)		—			—			(2,728	)
	Other adjustments		12			(8,242	)		(85	)		(8,315	)
	Balance at December 31, 2013	$	5,469,473		$	3,516,162		$	227,339		$	9,212,974
	Each of the Company’s operating segments described in Note 16 to these condensed consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within our international operations segments is considered a separate reporting unit.
	Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.
	The Company has applied a similar aggregation to the HCP operations in each region, to the vascular access service centers in its vascular access services reporting unit, to the physician practices in its physician services reporting unit, and to the dialysis centers within each sovereign international jurisdiction. For the Company’s additional operating segments, no component below the operating segment level is considered a discrete business and therefore these operating segments directly constitute individual reporting units.
	HCP’s current and expected future operating results have eroded recently, primarily as a result of reductions in its Medicare Advantage reimbursement rates. As a result, the Company has determined that two of its HCP reporting units, HCP California and HCP Nevada, are at risk of goodwill impairment. HCP California and HCP Nevada have goodwill of $2,511,477 and $517,618, respectively.
	The Company obtained preliminary third-party valuations of these two businesses as of June 30, 2014, noting that the estimated fair values of HCP California and HCP Nevada exceed their total carrying values by approximately 6.0% and 10.9%, respectively. Further reductions in HCP’s reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future.
	For example, a sustained, long-term reduction of 3% in operating income for HCP California and HCP Nevada could reduce their estimated fair values by up to 3.1% and 2.9%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California and HCP Nevada by up to 7.7% and 6.1%, respectively.
	During the first six months of 2014, the Company did not record any goodwill impairment charges. Except as described above, none of the goodwill associated with the Company’s various other reporting units was considered at risk of impairment as of June 30, 2014. Since the dates of the Company’s last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in circumstances that have affected the Company’s businesses. However, these did not cause management to believe it is more likely than not that the fair value of any of its reporting units would be less than its carrying amount.

Health_care_costs_payable

Health care costs payable	6 Months Ended
	Jun. 30, 2014
Health care costs payable	'
	6. Health care costs payable
	The health care costs shown in the following table include estimates for the cost of professional medical services provided by non-employed physicians and other providers, as well as inpatient and other ancillary costs for all markets, where state regulation allows for the assumption of global risk. Health care costs payable are included in medical payables.
	The following table shows the components of changes in the health care costs payable for the six months ended June 30, 2014:
		Six months ended
		June 30, 2014
	Health care costs payable, beginning of the period	$	172,310
	Add: Components of incurred health care costs
	Current year		775,604
	Prior years		5,602
	Total incurred health care costs		781,206
	Less: Claims paid
	Current year		589,968
	Prior years		153,223
	Total claims paid		743,191
	Health care costs payable, end of the period	$	210,325
	Our prior year estimates of health care costs payable increased by $5,602 resulting from certain medical claims being settled for amounts more than originally estimated. When significant increases (decreases) in prior-year health care cost estimates occur that we believe significantly impact our current year operating results, we disclose that amount as unfavorable (favorable) development of prior-year’s health care cost estimates. Actual claim payments for prior year services have not been materially different from our year-end estimates.

Income_taxes

Income taxes	6 Months Ended
	Jun. 30, 2014
Income taxes	'
	7. Income taxes
	As of June 30, 2014, the Company’s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $60,372, of which $32,945 would impact the Company’s effective tax rate if recognized. This balance represents a decrease of $166 from the December 31, 2013 balance of $60,538.
	The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At June 30, 2014 and December 31, 2013, the Company had approximately $11,969 and $10,742, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.
	As of June 30, 2014, it is reasonably possible that $27,427 of unrecognized tax benefits may be recognized within the next 12 months, primarily related to the filing of tax accounting method changes which will not impact the Company’s effective tax rate.

Longterm_debt

Long-term debt	6 Months Ended
	Jun. 30, 2014
Long-term debt	'
	8. Long-term debt
	Long-term debt was comprised of the following:
		June 30,			December 31,
		2014			2013
	Senior Secured Credit Facilities:
	New Term Loan A	$	1,000,000		$	—
	New Term Loan B		3,500,000			—
	Prior Term Loan A		—			800,000
	Prior Term Loan A-3		—			1,282,500
	Prior Term Loan B		—			1,697,500
	Prior Term Loan B-2		—			1,633,500
	Senior notes		4,066,907			2,800,000
	Acquisition obligations and other notes payable		66,511			67,352
	Capital lease obligations		183,647			152,751
	Total debt principal outstanding		8,817,065			8,433,603
	Discount on long-term debt		(17,500	)		(17,675	)
			8,799,565			8,415,928
	Less current portion		(408,987	)		(274,697	)
		$	8,390,578		$	8,141,231
	Classification of long-term debt at June 30, 2014 was as follows:
	Senior notes	$	291,907
	Current portion		117,080
	Total current portion		408,987
	Long-term debt		8,390,578
		$	8,799,565
	Scheduled maturities and pay-outs of long-term debt at June 30, 2014 were as follows:
	2014 (remainder of the year, including the 6 3⁄8% Senior Notes)		347,712
	2015		112,182
	2016		115,645
	2017		141,972
	2018		153,282
	2019		727,238
	Thereafter		7,219,034
	During the first six months of 2014, the Company made mandatory principal payments under its then existing Senior Secured Credit Facilities (before entering into a new senior secured credit agreement and repaying all outstanding amounts under the then existing Senior Secured Credit Facilities) totaling $37,500 on the Term Loan A, $16,875 on the Term Loan A-3, $4,375 on the Term Loan B and $4,125 on the Term Loan B-2.
	In June 2014, the Company entered into a $5,500,000 senior secured credit agreement (the New Credit Agreement). The New Credit Agreement consists of a five year Revolving Credit Facility in the aggregate principal amount of $1,000,000 (the New Revolver), a five year Term Loan A facility in the aggregate principal amount of $1,000,000 (the New Term Loan A) and a seven year Term Loan B facility in the aggregate principal amount of $3,500,000 (the New Term Loan B and collectively with the New Revolver and the New Term Loan A, the New Loans). In addition, the Company can increase the existing revolving commitments and enter into one or more incremental term loan facilities in an amount not to exceed the sum of $1,500,000 (less the amount of other permitted indebtedness incurred or issued in reliance on such amount), plus an amount of indebtedness such that the senior secured leverage ratio is not in excess of 3.50 to 1.00 after giving effect to such borrowings. The New Revolver and the New Term Loan A initially bears interest at LIBOR plus an interest rate margin of 1.75% which is subject to adjustment depending upon the Company’s leverage ratio and can range from 1.50% to 2.00%. The New Term Loan A requires annual principal payments beginning on September 30, 2014 of $25,000 in 2014, $50,000 in 2015, $62,500 in 2016, $87,500 in 2017 and $100,000 in 2018 with the balance of $675,000 due in 2019. The New Term Loan B bears interest at LIBOR (Floor of 0.75%) plus an interest rate margin of 2.75%. The New Term Loan B requires annual principal payments of $17,500 in 2014 and $35,000 for each year from 2015 through 2020, with the balance of $3,272,500 due in 2021. These New Loans under the New Credit Agreement are guaranteed by certain of the Company’s direct and indirect wholly-owned domestic subsidiaries holding most of the Company’s domestic assets and are secured by substantially all of the Company’s and the guarantors’ assets. The New Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on the amount of investments, acquisitions, the payment of dividends and redemptions and the incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company’s leverage ratio is below 3.50 to 1.00. In addition, the New Credit Agreement places limitations on the amount of tangible net assets of the non-guarantor subsidiaries and also requires compliance with a maximum leverage ratio covenant.
	In addition, in June 2014, the Company issued $1,750,000 5 1⁄8% Senior Notes due 2024 (the 5 1⁄8% Senior Notes). The 5 1⁄8% Senior Notes pay interest on January 15 and July 15 of each year beginning January 15, 2015. The 5 1⁄8% Senior Notes are unsecured obligations and will rank equally in right of payment with our existing and future unsecured senior indebtedness. The 5 1⁄8% Senior Notes are guaranteed by each of the Company’s domestic subsidiaries that guarantees the Company’s New Credit Agreement. The Company may redeem up to 35% of the 5 1⁄8% Senior Notes at any time prior to July 15, 2017 at a certain specified price from the proceeds of one or more equity offerings. In addition, the Company may redeem the 5 1⁄8% Senior Notes at any time prior to July 15, 2019 at make whole redemption prices and after such date at certain specified redemption prices.
	The Company received total proceeds from these borrowings of $6,250,000, $4,500,000 from the issuance of the New Term Loans and $1,750,000 from the issuance of the 5 1⁄8% Senior Notes. The Company used a portion of the proceeds to pay off the total outstanding principal balances under its then existing Senior Secured Credit Facilities plus accrued interest totaling $5,362,428 and in addition, to purchase pursuant to a cash tender offer $483,093 of the outstanding principal balances of the Company’s $775,000 6 3⁄8% Senior Notes due 2018 (6 3⁄8% Senior Notes) plus accrued interest and cash tender premium totaling $512,386. The total amount paid for the 6 3⁄8% Senior Notes from the cash tender offer was $1,051.25 per 1,000 of principal amount of the 6 3⁄8% Senior Notes, which resulted in the Company paying a cash tender premium of $24,759 for the redemption of this portion of the 6 3⁄8% Senior Notes. The Company also incurred an additional $81,569 in fees, discounts and other professional expenses associated with these transactions.
	In July 2014, the Company also purchased an additional $188 principal amount of the 6 3⁄8% Senior Notes plus accrued interest totaling $194 pursuant to the cash tender offer at a price of $1,021.25 per 1,000 of principal amount of the 6 3⁄8% Senior Notes, which resulted in the Company paying an additional cash tender premium of $4.
	In addition, in July 2014, the Company redeemed the remaining outstanding principal balance of the 6 3⁄8% Senior Notes of $291,719 at a redemption price of $1,047.81 per 1,000 of principal amount of the 6 3⁄8% Senior Notes plus accrued interest and a redemption premium which totaled $309,954. This resulted in an additional redemption premium of $13,947 being recorded as debt refinancing charges.
	As a result of these transactions, the Company recorded debt refinancing charges of $97,548 that consist of the cash tender premiums, the redemption premium, the write-off of existing deferred financing costs, the write-off of certain new refinancing costs, other professional fees and losses associated with the termination of several of the Company’s interest rate swap agreements.
	In addition, as a result of these transactions, the Company terminated $1,137,500 notional amounts of amortizing swaps and also terminated $600,000 of forward swaps during June 2014, that resulted in the Company recognizing a loss of $3,140, of which $2,972 was previously recorded in other comprehensive income due to the Company’s previously outstanding principal debt being paid-off as described above, and as a result of future forecasted transactions that are no longer probable. The loss is included as a component of the Company’s debt refinancing charges. During the six months ended June 30, 2014, the Company recognized debt expense of $6,137 from these swaps.
	The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company’s interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as the hedged forecasted cash flows occur, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, the Company has entered into several interest rate cap agreements that have the economic effect of capping the Company’s maximum exposure to LIBOR variable interest rate changes on specific portions of the Company’s floating rate debt, as described below. Certain cap agreements are also designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. Certain other cap agreements are ineffective cash flow hedges, and as a result, changes in the fair value of these cap agreements are reported in net income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The swap and cap agreements do not contain credit-risk contingent features.
	As of June 30, 2014, the Company maintains several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts of these swap agreements totaling $878,750. These agreements have the economic effect of modifying the LIBOR variable component of the Company’s interest rate on an equivalent amount of the Company’s New Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the New Term Loan A margin of 1.75%. The overall weighted average effective interest rate also includes the effects of $121,250 of unhedged New Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 1.75%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the six months ended June 30, 2014, the Company recognized debt expense of $1,592 from these swaps. As of June 30, 2014, the total fair value of these swap agreements was a net asset of approximately $849. The Company estimates that approximately $2,696 of existing unrealized pre-tax losses in other comprehensive income at June 30, 2014 will be reclassified into income over the next twelve months.
	As of June 30, 2014, the Company maintains several interest rate cap agreements that were entered into in March 2013 with notional amounts totaling $2,735,000 on the Company’s New Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 2.50% on an equivalent amount of the Company’s New Term Loan B. During the six months ended June 30, 2014, the Company recognized debt expense of $1,220 from these caps. The cap agreements expire on September 30, 2016. As of June 30, 2014, the total fair value of these cap agreements was an asset of approximately $2,692. During the six months ended June 30, 2014, the Company recorded a loss of $4,874 in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.
	As of June 30, 2014, the Company also maintains five other interest rate cap agreements with notional amounts totaling $1,250,000. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our New Term Loan B debt. However, as a result of the interest rate cap agreements that were entered into in March 2013, as described above, these interest rate cap agreements became ineffective cash flow hedges and as a result any changes in the fair value associated with these interest rate cap agreements will be charged to income. During the six months ended June 30, 2014, the Company recognized debt expense of $1,794 from these caps. The cap agreements expire on September 30, 2014.
	The following table summarizes the Company’s derivative instruments as of June 30, 2014 and December 31, 2013:
		June 30, 2014						December 31, 2013
	Derivatives designated as hedging	Balance sheet			Fair value			Balance sheet			Fair value
	instruments	location						location
	Interest rate swap agreements		Other short-term liabilities		$	2,696			Other short-term liabilities		$	12,069
	Interest rate swap agreements		Other long-term assets		$	3,545			Other long-term assets		$	10,004
	Interest rate cap agreements		Other long-term assets		$	2,692			Other long-term assets		$	7,567
	The following table summarizes the effects of the Company’s interest rate swap and cap agreements for the three and six months ended June 30, 2014 and 2013:
		Amount of gains												Location of	Amount of
		(losses) recognized in												losses reclassified	losses reclassified
		OCI on interest rate swap												from accumulated	from accumulated
		and cap agreements												OCI into income	OCI into income
	Derivatives designated	Three months ended						Six months ended							Three months ended						Six months ended
	as cash flow hedges	June 30,						June 30,							June 30,						June 30,
		2014			2013			2014			2013				2014			2013			2014			2013
	Interest rate swap agreements	$	(5,022	)	$	13,266		$	(7,786	)	$	12,302		Debt expense	$	(6,694	)	$	(4,159	)	$	(10,700	)	$	(7,366	)
														(including
														refinancing
													charges)
Interest rate cap agreements		(3,527	)		5,858			(4,874	)		2,945		Debt expense		(1,507	)		(1,507	)		(3,014	)		(2,404	)
													(including
													refinancing
													charges)
Tax benefit (expense)		3,340			(7,439	)		4,946			(5,931	)			3,204			2,204			5,358			3,801
Total	$	(5,209	)	$	11,685		$	(7,714	)	$	9,316			$	(4,997	)	$	(3,462	)	$	(8,356	)	$	(5,969	)
As of June 30, 2014, the interest rate on the Company’s New Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date and the New Term Loan B is also subject to interest rate caps if LIBOR should rise above 2.50%. See above for further details. Interest rates on the Company’s senior notes are fixed by their terms. The LIBOR variable component of the Company’s interest rate on a majority of the Company’s New Term Loan A is economically fixed as a result of interest rate swaps.
As a result of embedded LIBOR floors on the New Term Loan B debt agreement and the swap and cap agreements, the Company’s overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.51%, based upon the current margins in effect of 1.75% for the New Term Loan A and 2.75% for the New Term Loan B, as of June 30, 2014.
The Company’s overall weighted average effective interest rate during the second quarter of 2014 was 4.85% and as of June 30, 2014 was 4.56%.
As of June 30, 2014, the Company had undrawn revolving credit facilities totaling $1,000,000 of which approximately $83,000 was committed for outstanding letters of credit. In addition, HCP has an outstanding letter of credit of approximately $1,000 that is secured by a certificate of deposit.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Contingencies	'
	9. Contingencies
	The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.
	Inquiries by the Federal Government and Certain Related Civil Proceedings
	Vainer Private Civil Suit: In December 2008, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company has been in contact with the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC since November 2008 relating to this matter, and has been advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the qui tam provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.
	2010 U.S. Attorney Physician Relationship Investigation: In May 2010, the Company received a subpoena from the OIG’s office in Dallas, Texas. The civil subpoena covers the period from January 2005 to May 2010, and seeks production of a wide range of documents relating to the Company’s dialysis operations, including documents related to, among other things, financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. The Company has been advised by the attorneys conducting this civil investigation that they believe that some or all of the Company’s joint ventures do not comply with the anti-kickback statute and the False Claims Act. The Company disagrees that its joint venture structure generally, which the Company believes is widely used in the dialysis industry and other segments of the healthcare industry substantially in the form that the Company uses it, violates the federal anti-kickback statute or the False Claims Act. As to individual transactions, the Company made significant effort to ensure that its joint venture structures and process complied with the rules, but the Company is talking with the government about addressing its concerns. The focus of this investigation overlaps substantially with the 2011 U.S. Attorney Physician Relationship Investigation described below. The Company has agreed to a framework for a global resolution with the United States Attorney’s Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation of specific terms. The settlement will include the payment of approximately $389,000, entry into a corporate integrity agreement, the appointment of an independent compliance monitor, and the imposition of certain other business restrictions related to a subset of the Company’s joint venture arrangements. Under the terms of the framework for resolution, the Company has agreed to unwind a limited subset of joint ventures that were created through partial divestiture to nephrologists, and agreed not to enter into this type of partial divestiture joint venture with nephrologists in the future. In 2013, the Company accrued an estimated loss contingency reserve of $397,000 related to this matter. The final settlement remains subject to negotiation of specific terms and will continue to require management’s attention and significant legal expense. The Company can make no assurances as to the final outcome.
	2011 U.S. Attorney Physician Relationship Investigation: In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation relates to the Company’s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlaps substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. As noted above, the Company has agreed to a framework for a global resolution with the United States Attorney’s Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation of specific terms and will continue to require management’s attention and significant legal expense. The Company can make no assurances as to the final outcome.
	2011 U.S. Attorney Medicaid Investigation: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, we reached an agreement in principle to resolve this matter. The specific terms of a settlement remain subject to ongoing negotiation.
	Swoben Private Civil Suit: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the qui tam provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a qui tam action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.
	Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.
	In re DaVita HealthCare Partners Inc. Derivative Litigation: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that our directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.
	Other
	The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.
	A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company’s consolidated financial statements. The Company intends to continue to vigorously defend against the remaining claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company’s consolidated financial statements.
	In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

Noncontrolling_interests_subje

Noncontrolling interests subject to put provisions and other commitments	6 Months Ended
	Jun. 30, 2014
Noncontrolling interests subject to put provisions and other commitments	'
	10. Noncontrolling interests subject to put provisions and other commitments
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners’ discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners’ noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interest may ultimately be settled, which could vary significantly from the Company’s current estimates. The estimated fair values of noncontrolling interest subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers’ access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners’ noncontrolling interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial.
	Additionally, the Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics or medical practices that the Company operates under management and administrative service agreements of approximately $2,000.
	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

Longterm_incentive_compensatio

Long-term incentive compensation	6 Months Ended
	Jun. 30, 2014
Long-term incentive compensation	'
	11. Long-term incentive compensation
	Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to the dialysis and related lab services business, the HCP business, corporate support costs, and the ancillary services and strategic initiatives.
	The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.
	During the six months ended June 30, 2014, the Company granted 1,248 stock-settled stock appreciation rights with an aggregate grant-date fair value of $19,997 and a weighted-average expected life of approximately 4.2 years, and also granted 316 stock units with an aggregate grant-date fair value of $22,809 and a weighted-average expected life of approximately 3.4 years.
	For the six months ended June 30, 2014 and 2013, the Company recognized $52,960 and $38,773, respectively, in total LTIP expense, of which $29,699 and $32,266, respectively, was stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation through June 30, 2014 and 2013 was $10,997 and $12,171, respectively. As of June 30, 2014, there was $162,351 of total estimated unrecognized compensation cost for outstanding LTIP awards, including $99,331 related to stock-based compensation arrangements under the Company’s equity compensation and stock purchase plans. The Company expects to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.1 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.4 years.
	For the six months ended June 30, 2014 and 2013, the Company received $42,110 and $36,524, respectively, in actual tax benefits upon the exercise of stock awards.

Comprehensive_income

Comprehensive income	6 Months Ended
	Jun. 30, 2014
Comprehensive income	'
	12. Comprehensive income
		For the three months ended												For the six months ended
		30-Jun-14												30-Jun-14
		Interest			Investment			Foreign			Accumulated			Interest			Investment			Foreign			Accumulated
		rate swap			securities			currency			other			rate swap			securities			currency			other
		and cap						translation			comprehensive			and cap						translation			comprehensive
		agreements						adjustments			income (loss)			agreements						adjustments			income (loss)
	Beginning balance	$	(1,490	)	$	3,244		$	(3,393	)	$	(1,639	)	$	(2,344	)	$	3,120		$	(3,421	)	$	(2,645	)
	Unrealized (losses) gains		(8,549	)		875			1,939			(5,736	)		(12,660	)		1,405			1,967			(9,289	)
	Related income tax benefit (expense)		3,340			(297	)		—			3,044			4,946			(496	)		—			4,451
			(5,209	)		578			1,939			(2,692	)		(7,714	)		909			1,967			(4,838	)
	Reclassification from accumulated other comprehensive income into net income		8,201			—			—			8,201			13,714			(340	)		—			13,374
	Related tax		(3,204	)		—			—			(3,204	)		(5,358	)		133			—			(5,225	)
			4,997			—			—			4,997			8,356			(207	)		—			8,149
	Ending balance	$	(1,702	)	$	3,822		$	(1,454	)	$	666		$	(1,702	)	$	3,822		$	(1,454	)	$	666
		For the three months ended												For the six months ended
		30-Jun-13												30-Jun-13
		Interest			Investment			Foreign			Accumulated			Interest			Investment			Foreign			Accumulated
		rate swap			securities			currency			other			rate swap			securities			currency			other
		and cap						translation			comprehensive			and cap						translation			comprehensive
		agreements						adjustments			income (loss)			agreements						adjustments			income (loss)
	Beginning balance	$	(15,264	)	$	1,834		$	(3,311	)	$	(16,741	)	$	(15,402	)	$	1,310		$	(1,205	)	$	(15,297	)
	Unrealized gains (losses)		19,124			166			(1,841	)		17,449			15,247			1,178			(3,947	)		12,478
	Related income tax (expense) benefit		(7,439	)		(65	)		—			(7,504	)		(5,931	)		(459	)		—			(6,390	)
			11,685			101			(1,841	)		9,945			9,316			719			(3,947	)		6,088
	Reclassification from accumulated other comprehensive income into net income		5,666			—			—			5,666			9,770			(155	)		—			9,615
	Related tax		(2,204	)		—			—			(2,204	)		(3,801	)		61			—			(3,740	)
			3,462			—			—			3,462			5,969			(94	)		—			5,875
	Ending balance	$	(117	)	$	1,935		$	(5,152	)	$	(3,334	)	$	(117	)	$	1,935		$	(5,152	)	$	(3,334	)
	The reclassification of net swap and cap realized losses into income are recorded as debt expense in the corresponding condensed consolidated statements of income. See Note 8 to the condensed consolidated financial statements for further details.
	The reclassification of net investment realized gains into income are recorded in other income in the corresponding condensed consolidated statements of income. See Note 4 to the condensed consolidated financial statements for further details.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2014
Acquisitions	'
	13. Acquisitions
	During the first six months of 2014, the Company acquired dialysis businesses and other businesses consisting of one dialysis center located in the U.S., three dialysis centers located outside the U.S. and other medical businesses for a total of $98,442 in net cash and deferred purchase price obligations totaling $14,156. The assets and liabilities for all acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company’s condensed consolidated financial statements and operating results from the designated effective dates of the acquisitions. Certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of medical claims reserves and certain other working capital items relating to several of these acquisitions are pending final quantification.
	The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values:
		Six months ended
		June 30, 2014
	Tangible assets, principally leasehold improvements and equipment, net of cash	$	858
	Amortizable intangible and other long-term assets		69,366
	Goodwill		42,374
	Aggregate purchase price	$	112,598
	Amortizable intangible assets acquired during the first six months of 2014 had weighted-average estimated useful lives of 9.9 years. The total amount of goodwill deductible for tax purposes associated with these acquisitions was approximately $27,789.
	Contingent earn-out obligations
	The Company has several contingent earn-out obligations associated with acquisitions that could result in the Company paying the former shareholders of those acquired companies a total of up to $136,300 or a portion of that amount if certain EBITDA performance targets and quality margins are met over the next two years, if certain percentages of operating income are met over the next three years or if certain percentages of other annual EBITDA targets are met. As of June 30, 2014, the Company has estimated the fair value of these contingent earn-out obligations to be $38,335.
	Contingent earn-out obligations will be remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the re-measurement recorded in earnings. See Note 15 to the condensed consolidated financial statements for further details. Of the total contingent earn-out obligations of $38,335 recognized at June 30, 2014, a total of $13,682 is included in other liabilities and the remaining $24,653 is included in other long-term liabilities in the Company’s condensed consolidated balance sheet.
	The following is a reconciliation of changes in the contingent earn-out obligations for the six months ended June 30, 2014:
	Beginning balance, January 1, 2014	$	28,058
	Contingent earn-out obligations associated with acquisitions		13,772
	Remeasurement of fair value for other contingent earn-outs		(1,969	)
	Payments of contingent earn-outs		(1,526	)
		$	38,335

Variable_interest_entities

Variable interest entities	6 Months Ended
	Jun. 30, 2014
Variable interest entities	'
	14. Variable interest entities
	The Company relies on the operating activities of certain entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs).
	Under U.S. generally accepted accounting principles (GAAP), VIEs typically include (i) those for which the entity’s equity is not sufficient to finance its activities without additional subordinated financial support; (ii) those for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity’s economic performance, the obligation to absorb the entity’s expected losses, or the right to receive the entity’s expected returns; or (iii) those for which the voting rights of some investors are not proportional to their obligations to absorb the entity’s losses.
	Under U.S. GAAP, the Company has determined that substantially all of the entities it is associated with that qualify as VIEs must be included in its consolidated financial statements. The Company manages these entities and provides operating and capital funding as necessary for the entities to accomplish their operational and strategic objectives. A number of these entities are subject to nominee share ownership or share transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. In other cases the Company’s management agreements with these entities include both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for the entities to the Company. In some cases such entities are subject to broad exclusivity or noncompetition restrictions that benefit the Company. Further, in some cases the Company has contractual arrangements with its related party nominee owners that effectively indemnify these parties from the economic losses from, or entitle the Company to the economic benefits of, these entities.
	The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations. At June 30, 2014, these condensed consolidated financial statements include total assets of VIEs of $515,618 and total liabilities and noncontrolling interests of VIEs to third parties of $307,133.
	The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. See Note 4 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

Fair_value_of_financial_instru

Fair value of financial instruments	6 Months Ended
	Jun. 30, 2014
Fair value of financial instruments	'
	15. Fair value of financial instruments
	The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by the FASB.
	The following table summarizes the Company’s assets, liabilities and temporary equity measured at fair value on a recurring basis as of June 30, 2014:
		Total		Quoted prices in		Significant other		Significant
				active markets for		observable inputs		unobservable
				identical assets		(Level 2)		inputs
				(Level 1)				(Level 3)
	Assets
	Available-for-sale securities	$	25,685	$	25,685	$	—	$	—
	Interest rate cap agreements	$	2,692	$	—	$	2,692	$	—
	Interest rate swap agreements	$	3,545	$	—	$	3,545	$	—
	Funds on deposit with third parties	$	72,575	$	72,575	$	—	$	—
	Liabilities
	Contingent earn-out obligations	$	38,335	$	—	$	—	$	38,335
	Interest rate swap agreements	$	2,696	$	—	$	2,696	$	—
	Temporary equity
	Noncontrolling interests subject to put provisions	$	760,242	$	—	$	—	$	760,242
	The available for sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at fair value based upon quoted prices reported by each mutual fund. See Note 4 to these condensed consolidated financial statements for further discussion.
	The interest rate swap and cap agreements are recorded at fair value based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate swap and cap agreements would be materially different from the fair values currently reported. See Note 8 to the condensed consolidated financial statements for further discussion.
	The funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices.
	The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs including projected EBITDA, estimated probabilities of achieving gross margin of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair values of the quality results amounts. The estimated fair value of these contingent earn-out obligations will be remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value.
	See Note 10 to these condensed consolidated financial statements for a discussion of the Company’s methodology for estimating the fair value of noncontrolling interests subject to put obligations.
	Other financial instruments consist primarily of cash, accounts receivable, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at June 30, 2014 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company’s Senior Secured Credit Facilities totaled $4,482,500 as of June 30, 2014, and the fair value was approximately $4,526,300 based upon quoted market prices. The fair value of the Company’s senior notes was approximately $4,229,200 at June 30, 2014 based upon quoted market prices, as compared to the carrying amount of $4,066,907.

Segment_reporting

Segment reporting	6 Months Ended
	Jun. 30, 2014
Segment reporting	'
	16. Segment reporting
	The Company operates two major divisions, Kidney Care and HCP. The Kidney Care division is comprised of the Company’s U.S. dialysis and related lab services business and various other ancillary services and strategic initiatives, including its international dialysis operations. The HCP division is comprised of the Company’s HealthCare Partners integrated healthcare business.
	As of June 30, 2014, the Company’s ancillary services and strategic initiatives consisted primarily of pharmacy services, disease management services, vascular access services, ESRD clinical research programs, physician services, direct primary care and the Company’s international dialysis operations.
	The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker in making decisions about allocating resources to and assessing the financial results of the Company’s different business units. The chief operating decision maker for the Company is its Chief Executive Officer.
	The Company’s separate operating segments include its U.S. dialysis and related lab services business, its HCP operations in each region, each of its ancillary services and strategic initiatives, and its international operations in the European and Middle Eastern, Asia Pacific, and Latin American regions. The U.S. dialysis and related lab services business and the HCP business each qualify as separately reportable segments, and all of the other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category.
	The Company’s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial results of the operating segments. For internal management reporting, segment operations include direct segment operating expenses but exclude corporate support expenses, which consist primarily of indirect labor, benefits and long-term incentive based compensation of certain departments which provide support to all of the Company’s different operating lines of business. Corporate support expenses in the second quarter of 2014 have been reduced by internal management fees paid by the Company’s ancillary lines of businesses.
	The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
			Three months ended						Six months ended
			June 30,						June 30,
			2014			2013			2014			2013
	Segment net revenues:
	U.S. dialysis and related lab services
	Patient service revenues:
	External sources		$	2,096,605		$	1,980,267		$	4,125,349		$	3,889,050
	Intersegment revenues			9,084			8,158			16,916			15,669
	Total dialysis and related lab services revenues			2,105,689			1,988,425			4,142,265			3,904,719
	Less: Provision for uncollectible accounts			(84,227	)		(69,585	)		(165,690	)		(136,656	)
	Net dialysis and related lab services patient service revenues			2,021,462			1,918,840			3,976,575			3,768,063
	Other revenues(1)			3,579			3,424			6,732			6,319
	Total net dialysis and related lab services revenues			2,025,041			1,922,264			3,983,307			3,774,382
	HCP
	HCP revenues:
	Capitated revenues			783,182			692,357			1,554,724			1,438,428
	Net patient service revenues			58,076			49,433			114,297			103,035
	Other revenues(2)			46,029			19,216			58,553			23,302
	Intersegment capitated and other revenues			204			—			357			—
	Total revenues			887,491			761,006			1,727,931			1,564,765
	Other—Ancillary services and strategic initiatives
	Net patient service revenues—U.S.			4,709			3,050			8,862			6,490
	Net patient service revenues—International			24,035			13,294			47,281			24,357
	Capitated revenues			16,187			17,717			32,210			34,261
	Other external sources—U.S.			222,716			160,988			429,671			309,745
	Other external sources—International			1,598			1,512			3,276			2,924
	Intersegment revenues			4,474			3,397			9,293			6,176
	Total ancillary services and strategic initiatives revenues			273,719			199,958			530,593			383,953
	Total net segment revenues			3,186,251			2,883,228			6,241,831			5,723,100
	Elimination of intersegment revenues			(13,762	)		(11,555	)		(26,566	)		(21,845	)
	Consolidated net revenues		$	3,172,489		$	2,871,673		$	6,215,265		$	5,701,255
	Segment operating margin (loss):
	U.S. dialysis and related lab services		$	407,948		$	401,415		$	794,648		$	486,228
	HCP			82,048			81,382			136,002			189,466
	Other—Ancillary services and strategic initiatives			(1,920	)		(6,791	)		(243	)		(21,392	)
	Total segment margin			488,076			476,006			930,407			654,302
	Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
	Contingent earn-out obligation adjustment			—			56,977			—			56,977
	Corporate support expenses			(3,781	)		(10,963	)		(4,887	)		(22,398	)
	Consolidated operating income			484,295			522,020			925,520			688,881
	Debt expense			(106,132	)		(108,096	)		(212,467	)		(213,913	)
	Debt refinancing charges			(97,548	)		—			(97,548	)		—
	Other income (loss)			1,693			(1,374	)		3,391			(776	)
	Consolidated income from continuing operations before income taxes		$	282,308		$	412,550		$	618,896		$	474,192
	(1)	Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.
	(2)	Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.
	For the three months ended June 30, 2014, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was $99,163, $42,260 and $4,484, respectively.
	For the six months ended June 30, 2014, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was $195,606, $83,997 and $8,883, respectively.
	For the three months ended June 30, 2013, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was $88,588, $38,590 and $3,411, respectively.
	For the six months ended June 30, 2013, depreciation and amortization expense for the U.S. dialysis and related lab services, HCP and the ancillary services and strategic initiatives was $173,540, $76,607 and $6,351, respectively.
	Summary of assets by segment is as follows:
			June 30,			December 31,
			2014			2013
	Segment assets
	U.S. dialysis and related lab services		$	10,876,860		$	10,248,993
	HCP			6,369,644			6,265,767
Other—Ancillary services and strategic initiatives			679,067			584,117
Consolidated assets		$	17,925,571		$	17,098,877
For the three and six months ended June 30, 2014, the total amount of expenditures for property and equipment, excluding capital leases was $136,660 and $249,869, respectively, for the U.S. dialysis and related lab services, was $5,777 and $10,279, respectively, for HCP and was $9,594 and $18,445, respectively, for the ancillary services and strategic initiatives.
For the three and six months ended June 30, 2013, the total amount of expenditures for property and equipment, excluding capital leases was $128,699 and $230,775, respectively, for the U.S. dialysis and related lab services, and was $7,840 and $14,379, respectively, for HCP and was $5,133 and $13,242, respectively, for the ancillary services and strategic initiatives.

Changes_in_DaVita_HealthCare_P

Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries	6 Months Ended
	Jun. 30, 2014
Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries	'
	17. Changes in DaVita HealthCare Partners Inc.’s ownership interest in consolidated subsidiaries
	The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014		2013
	Net income attributable to DaVita HealthCare Partners Inc.	$	147,683		$	254,376		$	330,972	$	284,540
	(Decrease) increase in paid-in capital for sales of noncontrolling interests		(66	)		(78	)		15		(887	)
	Increase (decrease) in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest		1,247			(474	)		1,457		(474	)
	Net transfers to noncontrolling interests		1,181			(552	)		1,472		(1,361	)
	Change from net income attributable to DaVita HealthCare Partners Inc. and transfers to noncontrolling interests	$	148,864		$	253,824		$	332,444	$	283,179

New_accounting_standards

New accounting standards	6 Months Ended
	Jun. 30, 2014
New accounting standards	'
	18. New accounting standards
	In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in this ASU enhance convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). Part of the new definition of discontinued operation is based on elements of the definition of discontinued operations in IFRS 5, Non-Current Assets Held for Sale and Discontinued Operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s condensed consolidated financial statements.

Condensed_consolidating_financ

Condensed consolidating financial statements	6 Months Ended
	Jun. 30, 2014
Condensed consolidating financial statements	'
	19. Condensed consolidating financial statements
	The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company’s consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other administrative services. The Company’s senior notes are guaranteed by substantially all of its domestic wholly-owned subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, including by merger or consolidation or the sale of all equity interests in such subsidiary owned by the Company, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Non-wholly-owned subsidiaries, certain wholly-owned subsidiaries, foreign subsidiaries, joint ventures, partnerships, non-owned entities and third parties are not guarantors of these obligations.
	Condensed Consolidating Statements of Income
	For the three months ended June 30, 2014	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
		HealthCare			subsidiaries			subsidiaries			adjustments			total
		Partners Inc.
	Patient service revenues	$	—		$	1,517,268		$	668,312		$	1,669		$	2,187,249
	Less: Provision for uncollectible accounts		—			(57,281	)		(30,771	)		—			(88,052	)
	Net patient service revenues		—			1,459,987			637,541			1,669			2,099,197
	Capitated revenues		—			414,366			385,030			(27	)		799,369
	Other revenues		181,199			424,755			35,712			(367,743	)		273,923
	Total net revenues		181,199			2,299,108			1,058,283			(366,101	)		3,172,489
	Operating expenses		122,815			2,033,828			897,652			(366,101	)		2,688,194
	Operating income		58,384			265,280			160,631			—			484,295
	Debt expense, including debt refinancing charges		(202,258	)		(94,169	)		(10,180	)		102,927			(203,680	)
	Other income (expense)		99,532			4,166			922			(102,927	)		1,693
	Income tax (benefit) expense		(17,958	)		111,415			7,430			—			100,887
	Equity earnings in subsidiaries		174,067			110,205			—			(284,272	)		—
	Net income		147,683			174,067			143,943			(284,272	)		181,421
	Less: Net income attributable to noncontrolling interests		—			—			—			(33,738	)		(33,738	)
	Net income attributable to DaVita HealthCare Partners Inc.	$	147,683		$	174,067		$	143,943		$	(318,010	)	$	147,683
	For the three months ended June 30, 2013	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
		HealthCare			subsidiaries			subsidiaries			adjustments			total
		Partners Inc.
	Patient service revenues	$	—		$	1,476,135		$	581,208		$	(8,692	)	$	2,048,651
	Less: Provision for uncollectible accounts		—			(37,218	)		(34,973	)		—			(72,191	)
	Net patient service revenues		—			1,438,917			546,235			(8,692	)		1,976,460
	Capitated revenues		—			337,312			374,451			(1,689	)		710,074
	Other revenues		166,650			374,577			21,183			(377,271	)		185,139
	Total net revenues		166,650			2,150,806			941,869			(387,652	)		2,871,673
	Operating expenses		71,881			1,827,141			838,283			(387,652	)		2,349,653
	Operating income		94,769			323,665			103,586			—			522,020
	Debt expense		(107,337	)		(95,600	)		(11,247	)		106,088			(108,096	)
	Other income (expense)		100,947			3,714			53			(106,088	)		(1,374	)
	Income tax expense		29,458			97,729			2,005			—			129,192
	Equity earnings in subsidiaries		195,455			61,405			—			(256,860	)		—
	Net income		254,376			195,455			90,387			(256,860	)		283,358
	Less: Net income attributable to noncontrolling interests		—			—			—			(28,982	)		(28,982	)
	Net income attributable to DaVita HealthCare Partners Inc.	$	254,376		$	195,455		$	90,387		$	(285,842	)	$	254,376
	For the six months ended June 30, 2014	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
		HealthCare			subsidiaries			subsidiaries			adjustments			total
		Partners Inc.
	Patient service revenues	$	—		$	3,030,545		$	1,267,669		$	3,133		$	4,301,347
	Less: Provision for uncollectible accounts		—			(107,160	)		(64,089	)		—			(171,249	)
	Net patient service revenues		—			2,923,385			1,203,580			3,133			4,130,098
	Capitated revenues		—			818,913			768,428			(407	)		1,586,934
	Other revenues		344,242			818,310			68,003			(732,322	)		498,233
	Total net revenues		344,242			4,560,608			2,040,011			(729,596	)		6,215,265
	Operating expenses		235,112			4,014,282			1,769,947			(729,596	)		5,289,745
	Operating income		109,130			546,326			270,064			—			925,520
	Debt expense, including debt refinancing charges		(307,541	)		(188,806	)		(19,932	)		206,264			(310,015	)
	Other income (expense)		199,475			8,935			1,245			(206,264	)		3,391
	Income tax expense		431			215,546			9,761			—			225,738
	Equity earnings in subsidiaries		330,339			179,430			—			(509,769	)		—
	Net income		330,972			330,339			241,616			(509,769	)		393,158
	Less: Net income attributable to noncontrolling interests		—			—			—			(62,186	)		(62,186	)
	Net income attributable to DaVita HealthCare Partners Inc.	$	330,972		$	330,339		$	241,616		$	(571,955	)	$	330,972
	For the six months ended June 30, 2013	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
		HealthCare			subsidiaries			subsidiaries			adjustments			total
		Partners Inc.
	Patient service revenues	$	—		$	2,928,355		$	1,117,866		$	(17,697	)	$	4,028,524
	Less: Provision for uncollectible accounts		—			(101,075	)		(41,173	)		—			(142,248	)
	Net patient service revenues		—			2,827,280			1,076,693			(17,697	)		3,886,276
Capitated revenues		—			697,336			778,126			(2,773	)		1,472,689
Other revenues		302,025			733,034			38,840			(731,609	)		342,290
Total net revenues		302,025			4,257,650			1,893,659			(752,079	)		5,701,255
Operating expenses		192,385			3,908,364			1,663,704			(752,079	)		5,012,374
Operating income		109,640			349,286			229,955			—			688,881
Debt expense		(212,668	)		(190,315	)		(21,970	)		211,040			(213,913	)
Other income (expense)		201,168			9,681			(585	)		(211,040	)		(776	)
Income tax expense		34,055			94,517			15,764			—			144,336
Equity earnings in subsidiaries		220,455			127,482			—			(347,937	)		—
Income from continuing operations		284,540			201,617			191,636			(347,937	)		329,856
Discontinued operations		—			—			13,236			—			13,236
Net income		284,540			201,617			204,872			(347,937	)		343,092
Less: Net income attributable to noncontrolling interests		—			—			—			(58,552	)		(58,552	)
Net income attributable to DaVita HealthCare Partners Inc.	$	284,540		$	201,617		$	204,872		$	(406,489	)	$	284,540
Condensed Consolidating Statements of Comprehensive Income
For the three months ended June 30, 2014	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
	HealthCare			subsidiaries			subsidiaries			adjustments			total
	Partners Inc.
Net income	$	147,683		$	174,067		$	143,943		$	(284,272	)	$	181,421
Other comprehensive income		2,305			—			—			—			2,305
Total comprehensive income		149,988			174,067			143,943			(284,272	)		183,726
Less: comprehensive income attributable to the noncontrolling interests		—			—			—			(33,738	)		(33,738	)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$	149,988		$	174,067		$	143,943		$	(318,010	)	$	149,988
For the three months ended June 30, 2013
Net income	$	254,376		$	195,455		$	90,387		$	(256,860	)	$	283,358
Other comprehensive income		13,407			—			—			—			13,407
Total comprehensive income		267,783			195,455			90,387			(256,860	)		296,765
Less: comprehensive income attributable to the noncontrolling interests		—			—			—			(28,982	)		(28,982	)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$	267,783		$	195,455		$	90,387		$	(285,842	)	$	267,783
For the six months ended June 30, 2014	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
	HealthCare			subsidiaries			subsidiaries			adjustments			total
	Partners Inc.
Net income	$	330,972		$	330,339		$	241,616		$	(509,769	)	$	393,158
Other comprehensive income		3,311			—			—			—			3,311
Total comprehensive income		334,283			330,339			241,616			(509,769	)		396,469
Less: comprehensive income attributable to the noncontrolling interests		—			—			—			(62,186	)		(62,186	)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$	334,283		$	330,339		$	241,616		$	(571,955	)	$	334,283
For the six months ended June 30, 2013
Net income	$	284,540		$	201,617		$	204,872		$	(347,937	)	$	343,092
Other comprehensive income		11,963			—			—			—			11,963
Total comprehensive income		296,503			201,617			204,872			(347,937	)		355,055
Less: comprehensive income attributable to the noncontrolling interests		—			—			—			(58,552	)		(58,552	)
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$	296,503		$	201,617		$	204,872		$	(406,489	)	$	296,503
Condensed Consolidating Balance Sheets
As of June 30, 2014	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
	HealthCare			subsidiaries			subsidiaries			adjustments			total
	Partners Inc.
Cash and cash equivalents	$	1,081,021		$	137,229		$	202,723		$	—		$	1,420,973
Accounts receivable, net		—			953,474			596,778			—			1,550,252
Other current assets		83,242			971,776			135,004			—			1,190,022
Total current assets		1,164,263			2,062,479			934,505			—			4,161,247
Property and equipment, net		187,939			1,394,182			708,723			—			2,290,844
Amortizable intangibles, net		92,421			1,867,978			62,476			—			2,022,875
Investments in subsidiaries		8,784,145			1,589,418			—			(10,373,563	)		—
Intercompany receivables		3,645,401			—			545,592			(4,190,993	)		—
Other long-term assets and investments		59,487			62,812			74,263			—			196,562
Goodwill		—			7,875,336			1,378,707			—			9,254,043
Total assets	$	13,933,656		$	14,852,205		$	3,704,266		$	(14,564,556	)	$	17,925,571
Current liabilities		496,066			1,744,652			367,430			—			2,608,148
Intercompany payables		—			3,115,717			1,075,276			(4,190,993	)		—
Long-term debt and other long-term liabilities		8,157,874			1,207,691			234,791			—			9,600,356
Noncontrolling interests subject to put provisions		493,945			—			—			266,297			760,242
Total DaVita HealthCare Partners Inc. shareholders’ equity		4,785,771			8,784,145			1,589,418			(10,373,563	)		4,785,771
Noncontrolling interests not subject to put provisions		—			—			437,351			(266,297	)		171,054
Total equity		4,785,771			8,784,145			2,026,769			(10,639,860	)		4,956,825
Total liabilities and equity	$	13,933,656		$	14,852,205		$	3,704,266		$	(14,564,556	)	$	17,925,571
As of December 31, 2013	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
	HealthCare			subsidiaries			subsidiaries			adjustments			total
	Partners Inc.
Cash and cash equivalents	$	602,188		$	175,004		$	169,057		$	—		$	946,249
Accounts receivable, net		—			939,543			545,620			—			1,485,163
Other current assets		27,910			908,010			104,946			—			1,040,866
Total current assets		630,098			2,022,557			819,623			—			3,472,278
Property and equipment, net		177,633			1,377,924			633,854			—			2,189,411
Amortizable intangibles, net		77,531			1,882,685			64,157			—			2,024,373
Investments in subsidiaries		8,231,059			1,389,558			—			(9,620,617	)		—
Intercompany receivables		3,983,214			—			480,993			(4,464,207	)		—
Other long-term assets and investments		61,391			67,402			71,048			—			199,841
Goodwill		—			7,837,421			1,375,553			—			9,212,974
Total assets	$	13,160,926		$	14,577,547		$	3,445,228		$	(14,084,824	)	$	17,098,877
Current liabilities	$	328,875		$	1,774,634		$	358,540		$	—		$	2,462,049
Intercompany payables		—			3,421,198			1,043,009			(4,464,207	)		—
Long-term debt and other long-term liabilities		7,948,390			1,150,656			234,941			—			9,333,987
Noncontrolling interests subject to put provisions		451,182			—			—			246,118			697,300
Total DaVita HealthCare Partners Inc. shareholders’ equity		4,432,479			8,231,059			1,389,558			(9,620,617	)		4,432,479
Noncontrolling interests not subject to put provisions		—			—			419,180			(246,118	)		173,062
Total equity		4,432,479			8,231,059			1,808,738			(9,866,735	)		4,605,541
Total liabilities and equity	$	13,160,926		$	14,577,547		$	3,445,228		$	(14,084,824	)	$	17,098,877
Condensed Consolidating Statements of Cash Flows
For the six months ended June 30, 2014	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
	HealthCare			subsidiaries			subsidiaries			adjustments			total
	Partners Inc.
Cash flows from operating activities:
Net income	$	330,972		$	330,339		$	241,616		$	(509,769	)	$	393,158
Changes in operating assets and liabilities and non-cash items included in net income		(191,299	)		7,007			(37,137	)		509,769			288,340
Net cash provided by operating activities		139,673			337,346			204,479			—			681,498
Cash flows from investing activities:
Additions of property and equipment, net		(25,377	)		(123,519	)		(129,697	)		—			(278,593	)
Acquisitions		—			(97,057	)		(1,385	)		—			(98,442	)
Proceeds from asset and business sales		—			215			—			—			215
Purchases/proceeds from investment sales and other items		(58,496	)		(5,263	)		(2,276	)		—			(66,035	)
Net cash used in investing activities		(83,873	)		(225,624	)		(133,358	)		—			(442,855	)
Cash flows from financing activities:
Long-term debt and related financing costs, net		353,406			(7,158	)		2,188			—			348,436
Intercompany borrowing		139,052			(137,529	)		(1,523	)		—			—
Other items		(69,425	)		(4,810	)		(37,553	)		—			(111,788	)
Net cash provided by (used in) financing activities		423,033			(149,497	)		(36,888	)		—			236,648
Effect of exchange rate changes on cash		—			—			(567	)		—			(567	)
Net increase (decrease) in cash and cash equivalents		478,833			(37,775	)		33,666			—			474,724
Cash and cash equivalents at beginning of period		602,188			175,004			169,057			—			946,249
Cash and cash equivalents at end of period	$	1,081,021		$	137,229		$	202,723		$	—		$	1,420,973
For the six months ended June 30, 2013	DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
	HealthCare			subsidiaries			subsidiaries			adjustments			total
	Partners Inc.
Cash flows from operating activities:
Net income	$	284,540		$	201,617		$	204,872		$	(347,937	)	$	343,092
Changes in operating assets and liabilities and non-cash items included in net income		(271,776	)		288,254			(21,481	)		347,937			342,934
Net cash provided by operating activities		12,764			489,871			183,391			—			686,026
Cash flows from investing activities:
Additions of property and equipment, net		(24,213	)		(131,671	)		(102,512	)		—			(258,396	)
Acquisitions		—			(119,818	)		(32,294	)		—			(152,112	)
Proceeds from asset sales		60,650			3,713			—			—			64,363
Purchases of investments and other items		(2,201	)		359			100			—			(1,742	)
Net cash provided by (used in) investing activities		34,236			(247,417	)		(134,706	)		—			(347,887	)
Cash flows from financing activities:
Long-term debt and related financing costs, net		(238,400	)		(5,496	)		(7,472	)		—			(251,368	)
Intercompany borrowing		250,330			(284,739	)		34,409			—			—
Other items		37,264			5,429			(45,074	)		—			(2,381	)
Net cash provided by (used in) financing activities		49,194			(284,806	)		(18,137	)		—			(253,749	)
Effect of exchange rate changes on cash		—			—			(234	)		—			(234	)
Net increase (decrease) in cash and cash equivalents		96,194			(42,352	)		30,314			—			84,156
Cash and cash equivalents at beginning of period		195,037			166,107			172,604			—			533,748
Cash and cash equivalents at end of period	$	291,231		$	123,755		$	202,918		$	—		$	617,904

Supplemental_data

Supplemental data	6 Months Ended
	Jun. 30, 2014
Supplemental data	'
	20. Supplemental data
	The following information is presented as supplemental data as required by the indentures governing our senior notes.
	Condensed Consolidating Statements of Income
	For the three months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Patient service operating revenues		$	2,187,249		$	29,361		$	—		$	2,157,888
	Less: Provision for uncollectible accounts			(88,052	)		(1,979	)		—			(86,073	)
	Net patient service operating revenues			2,099,197			27,382			—			2,071,815
	Capitated revenues			799,369			368,551			—			430,818
	Other revenues			273,923			2,313			—			271,610
	Total net operating revenues			3,172,489			398,246			—			2,774,243
	Operating expenses			2,688,194			386,281			(16	)		2,301,929
	Operating income			484,295			11,965			16			472,314
	Debt expense, including refinancing charges			(203,680	)		(3,423	)		—			(200,257	)
	Other income			1,693			25			—			1,668
	Income tax expense			100,887			2,712			7			98,168
	Net income			181,421			5,855			9			175,557
	Minority interests			(33,738	)		—			—			(33,738	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	147,683		$	5,855		$	9		$	141,819
	For the six months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Patient service operating revenues		$	4,301,347		$	60,500		$	—		$	4,240,847
	Less: Provision for uncollectible accounts			(171,249	)		(2,589	)		—			(168,660	)
	Net patient service operating revenues			4,130,098			57,911			—			4,072,187
	Capitated revenues			1,586,934			734,680			—			852,254
	Other revenues			498,233			2,879			—			495,354
	Total net operating revenues			6,215,265			795,470			—			5,419,795
	Operating expenses			5,289,745			775,799			236			4,513,710
	Operating income			925,520			19,671			(236	)		906,085
	Debt expense, including refinancing charges			(310,015	)		(6,618	)		—			(303,397	)
	Other income			3,391			33			—			3,358
	Income tax expense			225,738			4,157			(94	)		221,675
	Net income			393,158			8,929			(142	)		384,371
	Minority interests			(62,186	)		—			—			(62,186	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	330,972		$	8,929		$	(142	)	$	322,185
	(1)	After the elimination of the unrestricted subsidiaries and the physician groups
	Condensed Consolidating Statements of Comprehensive Income
	For the three months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Net income		$	181,421		$	5,855		$	9		$	175,557
	Other comprehensive income			2,305			—			—			2,305
	Total comprehensive income			183,726			5,855			9			177,862
	Less: comprehensive income attributable to the noncontrolling interests			(33,738	)		—			—			(33,738	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	149,988		$	5,855		$	9		$	144,124
	For the six months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Net income		$	393,158		$	8,929		$	(142	)	$	384,371
	Other comprehensive income			3,311			—			—			3,311
	Total comprehensive income			396,469			8,929			(142	)		387,682
	Less: comprehensive income attributable to the noncontrolling interests			(62,186	)		—			—			(62,186	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	334,283		$	8,929		$	(142	)	$	325,496
	(1)	After the elimination of the unrestricted subsidiaries and the physician groups
	Condensed Consolidating Balance Sheets
	As of June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Cash and cash equivalents		$	1,420,973		$	117,313		$	—		$	1,303,660
	Accounts receivable, net			1,550,252			239,428			—			1,310,824
	Other current assets			1,190,022			27,776			—			1,162,246
Total current assets			4,161,247			384,517			—			3,776,730
Property and equipment, net			2,290,844			5,006			—			2,285,838
Amortizable intangibles, net			2,022,875			6,794			—			2,016,081
Other long-term assets			196,562			69,311			3,089			124,162
Goodwill			9,254,043			9,181			—			9,244,862
Total assets		$	17,925,571		$	474,809		$	3,089		$	17,447,673
Current liabilities		$	2,608,148		$	175,238		$	—		$	2,432,910
Payables to parent			—			202,448			3,089			(205,537	)
Long-term debt and other long-term liabilities			9,600,356			83,106			—			9,517,250
Noncontrolling interests subject to put provisions			760,242			—			—			760,242
Total DaVita HealthCare Partners Inc. shareholders’ equity			4,785,771			14,017			—			4,771,754
Noncontrolling interests not subject to put provisions			171,054			—			—			171,054
Shareholders’ equity			4,956,825			14,017			—			4,942,808
Total liabilities and shareholder’s equity		$	17,925,571		$	474,809		$	3,089		$	17,447,673
As of December 31, 2013		Consolidated			Physician			Unrestricted			Company and
		Total			Groups			Subsidiaries			Restricted
											Subsidiaries(1)
Cash and cash equivalents		$	946,249		$	127,309		$	—		$	818,940
Accounts receivable, net			1,485,163			235,463			—			1,249,700
Other current assets			1,040,866			35,640			—			1,005,226
Total current assets			3,472,278			398,412			—			3,073,866
Property and equipment, net			2,189,411			5,541			—			2,183,870
Amortizable intangibles, net			2,024,373			7,283			—			2,017,090
Other long-term assets			199,841			64,013			3,325			132,503
Goodwill			9,212,974			8,981			—			9,203,993
Total assets		$	17,098,877		$	484,230		$	3,325		$	16,611,322
Current liabilities		$	2,462,049		$	193,079		$	—		$	2,268,970
Payables to parent			—			194,958			3,325			(198,283	)
Long-term debt and other long-term liabilities			9,333,987			94,727			—			9,239,260
Noncontrolling interests subject to put provisions			697,300			—			—			697,300
Total DaVita HealthCare Partners Inc. shareholders’ equity			4,432,479			1,466			—			4,431,013
Noncontrolling interests not subject to put provisions			173,062			—			—			173,062
Shareholders’ equity			4,605,541			1,466			—			4,604,075
Total liabilities and shareholder’s equity		$	17,098,877		$	484,230		$	3,325		$	16,611,322
(1)	After the elimination of the unrestricted subsidiaries and the physician groups
Condensed Consolidating Statements of Cash Flows
For the six months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
		Total			Groups			Subsidiaries			Restricted
											Subsidiaries(1)
Cash flows from operating activities:
Net income		$	393,158		$	8,929		$	(142	)	$	384,371
Changes in operating and intercompany assets and liabilities and non-cash items included in net income			288,340			(27,961	)		142			316,159
Net cash provided by (used in) operating activities			681,498			(19,032	)		—			700,530
Cash flows from investing activities:
Additions of property and equipment			(278,593	)		(20	)		—			(278,573	)
Acquisitions and divestitures, net			(98,442	)		—			—			(98,442	)
Proceeds from discontinued operations			215			—			—			215
Investments and other items			(66,035	)		(2,276	)		—			(63,759	)
Net cash used in investing activities			(442,855	)		(2,296	)		—			(440,559	)
Cash flows from financing activities:
Long-term debt			348,436			—			—			348,436
Intercompany			—			11,332			—			(11,332	)
Other items			(111,788	)		—			—			(111,788	)
Net cash provided by financing activities			236,648			11,332			—			225,316
Effect of exchange rate changes on cash			(567	)		—			—			(567	)
Net increase (decrease) in cash			474,724			(9,996	)		—			484,720
Cash at beginning of year			946,249			127,309			—			818,940
Cash at end of year		$	1,420,973		$	117,313		$	—		$	1,303,660
(1)	After the elimination of the unrestricted subsidiaries and the physician groups

Earnings_per_share_Tables

Earnings per share (Tables)	6 Months Ended
	Jun. 30, 2014
Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Earnings Per Share	'
	The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows:
			Three months ended						Six months ended
			June 30,						June 30,
			2014			2013			2014			2013
	Basic:
	Income from continuing operations attributable to DaVita HealthCare Partners Inc.		$	147,683		$	254,376		$	330,972		$	271,291
	Increase in noncontrolling interests redemption rights in excess of fair value			—			(259	)		—			(259	)
	Income from continuing operations for basic earnings per share calculation		$	147,683		$	254,117		$	330,972		$	271,032
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			—			—			13,249
	Net income attributable to DaVita HealthCare Partners Inc. for basic earnings per share calculation		$	147,683		$	254,117		$	330,972		$	284,281
	Weighted average shares outstanding during the period			214,451			211,986			214,010			211,574
	Vested stock units			2			5			2			5
	Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger			(2,194	)		(2,194	)		(2,194	)		(2,194	)
	Weighted average shares for basic earnings per share calculation			212,259			209,797			211,818			209,385
	Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.		$	0.7		$	1.21		$	1.56		$	1.29
	Basic income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.		$	—		$	—		$	—		$	0.07
	Basic net income per share attributable to DaVita HealthCare Partners Inc.		$	0.7		$	1.21		$	1.56		$	1.36
	Diluted:
	Income from continuing operations attributable to DaVita HealthCare Partners Inc.		$	147,683		$	254,376		$	330,972		$	271,291
	Increase in noncontrolling interests redemption rights in excess of fair value			—			(259	)		—			(259	)
	Income from continuing operations for diluted earnings per share calculation		$	147,683		$	254,117		$	330,972		$	271,032
	Discontinued operations attributable to DaVita HealthCare Partners Inc.			—			—			—			13,249
	Net income attributable to DaVita HealthCare Partners Inc. for diluted earnings per share calculation		$	147,683		$	254,117		$	330,972		$	284,281
	Weighted average shares outstanding during the period			214,451			211,986			214,010			211,574
	Vested stock units			2			5			2			5
	Assumed incremental shares from stock plans			2,268			2,858			2,409			2,911
	Weighted average shares for diluted earnings per share calculation			216,721			214,849			216,421			214,490
	Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.		$	0.68		$	1.18		$	1.53		$	1.26
	Diluted income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.		$	—		$	—		$	—		$	0.07
	Diluted net income per share attributable to DaVita HealthCare Partners Inc.		$	0.68		$	1.18		$	1.53		$	1.33
	Anti-dilutive stock-settled awards excluded from calculation(1)			990			4,520			1,995			3,353
	(1)	Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Investments_in_debt_and_equity1

Investments in debt and equity securities and other investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments	'
	The Company’s investments in securities consist of the following:
		June 30, 2014						December 31, 2013
		Held to		Available		Total		Held to		Available		Total
		maturity		for sale				maturity		for sale
	Certificates of deposit and money market funds due within one year	$	62,374	$	—	$	62,374	$	5,601	$	—	$	5,601
	Investments in mutual funds and common stock		—		25,685		25,685		—		19,421		19,421
		$	62,374	$	25,685	$	88,059	$	5,601	$	19,421	$	25,022
	Short-term investments	$	62,374	$	1,461	$	63,835	$	5,601	$	1,200	$	6,801
	Long-term investments		—		24,224		24,224		—		18,221		18,221
		$	62,374	$	25,685	$	88,059	$	5,601	$	19,421	$	25,022

Goodwill_Tables

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2014
Changes in Goodwill by Reportable Segments	'
	Changes in goodwill by reportable segments were as follows:
		Six months ended June 30, 2014
		U.S. dialysis and			HCP			Other-ancillary			Consolidated total
		related lab services						services and
								strategic initiatives
	Balance at December 31, 2013	$	5,469,473		$	3,516,162		$	227,339		$	9,212,974
	Acquisitions		2,915			38,639			820			42,374
	Other adjustments		—			(2,277	)		972			(1,305	)
	Balance at June 30, 2014	$	5,472,388		$	3,552,524		$	229,131		$	9,254,043
		Year ended December 31, 2013
		U.S. dialysis and			HCP			Other-ancillary			Consolidated total
		related lab services						services and
								strategic initiatives
	Balance at December 31, 2012	$	5,309,152		$	3,506,571		$	137,027		$	8,952,750
	Acquisitions		163,037			17,833			90,397			271,267
	Divestitures		(2,728	)		—			—			(2,728	)
	Other adjustments		12			(8,242	)		(85	)		(8,315	)
	Balance at December 31, 2013	$	5,469,473		$	3,516,162		$	227,339		$	9,212,974

Health_care_costs_payable_Tabl

Health care costs payable (Tables)	6 Months Ended
	Jun. 30, 2014
Components of Changes in Health Care Costs Payable	'
	The following table shows the components of changes in the health care costs payable for the six months ended June 30, 2014:
		Six months ended
		June 30, 2014
	Health care costs payable, beginning of the period	$	172,310
	Add: Components of incurred health care costs
	Current year		775,604
	Prior years		5,602
	Total incurred health care costs		781,206
	Less: Claims paid
	Current year		589,968
	Prior years		153,223
	Total claims paid		743,191
	Health care costs payable, end of the period	$	210,325

Longterm_debt_Tables

Long-term debt (Tables)	6 Months Ended
	Jun. 30, 2014
Long Term Debt	'
	Long-term debt was comprised of the following:
		June 30,			December 31,
		2014			2013
	Senior Secured Credit Facilities:
	New Term Loan A	$	1,000,000		$	—
	New Term Loan B		3,500,000			—
	Prior Term Loan A		—			800,000
	Prior Term Loan A-3		—			1,282,500
	Prior Term Loan B		—			1,697,500
	Prior Term Loan B-2		—			1,633,500
	Senior notes		4,066,907			2,800,000
	Acquisition obligations and other notes payable		66,511			67,352
	Capital lease obligations		183,647			152,751
	Total debt principal outstanding		8,817,065			8,433,603
	Discount on long-term debt		(17,500	)		(17,675	)
			8,799,565			8,415,928
	Less current portion		(408,987	)		(274,697	)
		$	8,390,578		$	8,141,231
Classification of Long Term Debt	'
	Classification of long-term debt at June 30, 2014 was as follows:
	Senior notes	$	291,907
	Current portion		117,080
	Total current portion		408,987
	Long-term debt		8,390,578
		$	8,799,565
Scheduled Maturities of Long-term Debt	'
	Scheduled maturities and pay-outs of long-term debt at June 30, 2014 were as follows:
	2014 (remainder of the year, including the 6 3⁄8% Senior Notes)		347,712
	2015		112,182
	2016		115,645
	2017		141,972
	2018		153,282
	2019		727,238
	Thereafter		7,219,034
Derivative Instruments	'
	The following table summarizes the Company’s derivative instruments as of June 30, 2014 and December 31, 2013:
		June 30, 2014						December 31, 2013
	Derivatives designated as hedging	Balance sheet			Fair value			Balance sheet			Fair value
	instruments	location						location
	Interest rate swap agreements		Other short-term liabilities		$	2,696			Other short-term liabilities		$	12,069
	Interest rate swap agreements		Other long-term assets		$	3,545			Other long-term assets		$	10,004
	Interest rate cap agreements		Other long-term assets		$	2,692			Other long-term assets		$	7,567
Effects of Interest Rate Swap Agreements	'
	The following table summarizes the effects of the Company’s interest rate swap and cap agreements for the three and six months ended June 30, 2014 and 2013:
		Amount of gains												Location of	Amount of
		(losses) recognized in												losses reclassified	losses reclassified
		OCI on interest rate swap												from accumulated	from accumulated
		and cap agreements												OCI into income	OCI into income
	Derivatives designated	Three months ended						Six months ended							Three months ended						Six months ended
	as cash flow hedges	June 30,						June 30,							June 30,						June 30,
		2014			2013			2014			2013				2014			2013			2014			2013
	Interest rate swap agreements	$	(5,022	)	$	13,266		$	(7,786	)	$	12,302		Debt expense	$	(6,694	)	$	(4,159	)	$	(10,700	)	$	(7,366	)
														(including
														refinancing
														charges)
	Interest rate cap agreements		(3,527	)		5,858			(4,874	)		2,945		Debt expense		(1,507	)		(1,507	)		(3,014	)		(2,404	)
														(including
														refinancing
														charges)
	Tax benefit (expense)		3,340			(7,439	)		4,946			(5,931	)			3,204			2,204			5,358			3,801
	Total	$	(5,209	)	$	11,685		$	(7,714	)	$	9,316			$	(4,997	)	$	(3,462	)	$	(8,356	)	$	(5,969	)

Comprehensive_income_Tables

Comprehensive income (Tables)	6 Months Ended
	Jun. 30, 2014
Comprehensive income	'
		For the three months ended												For the six months ended
		30-Jun-14												30-Jun-14
		Interest			Investment			Foreign			Accumulated			Interest			Investment			Foreign			Accumulated
		rate swap			securities			currency			other			rate swap			securities			currency			other
		and cap						translation			comprehensive			and cap						translation			comprehensive
		agreements						adjustments			income (loss)			agreements						adjustments			income (loss)
	Beginning balance	$	(1,490	)	$	3,244		$	(3,393	)	$	(1,639	)	$	(2,344	)	$	3,120		$	(3,421	)	$	(2,645	)
	Unrealized (losses) gains		(8,549	)		875			1,939			(5,736	)		(12,660	)		1,405			1,967			(9,289	)
	Related income tax benefit (expense)		3,340			(297	)		—			3,044			4,946			(496	)		—			4,451
			(5,209	)		578			1,939			(2,692	)		(7,714	)		909			1,967			(4,838	)
	Reclassification from accumulated other comprehensive income into net income		8,201			—			—			8,201			13,714			(340	)		—			13,374
	Related tax		(3,204	)		—			—			(3,204	)		(5,358	)		133			—			(5,225	)
			4,997			—			—			4,997			8,356			(207	)		—			8,149
	Ending balance	$	(1,702	)	$	3,822		$	(1,454	)	$	666		$	(1,702	)	$	3,822		$	(1,454	)	$	666
		For the three months ended												For the six months ended
		30-Jun-13												30-Jun-13
		Interest			Investment			Foreign			Accumulated			Interest			Investment			Foreign			Accumulated
		rate swap			securities			currency			other			rate swap			securities			currency			other
		and cap						translation			comprehensive			and cap						translation			comprehensive
		agreements						adjustments			income (loss)			agreements						adjustments			income (loss)
	Beginning balance	$	(15,264	)	$	1,834		$	(3,311	)	$	(16,741	)	$	(15,402	)	$	1,310		$	(1,205	)	$	(15,297	)
	Unrealized gains (losses)		19,124			166			(1,841	)		17,449			15,247			1,178			(3,947	)		12,478
	Related income tax (expense) benefit		(7,439	)		(65	)		—			(7,504	)		(5,931	)		(459	)		—			(6,390	)
			11,685			101			(1,841	)		9,945			9,316			719			(3,947	)		6,088
	Reclassification from accumulated other comprehensive income into net income		5,666			—			—			5,666			9,770			(155	)		—			9,615
	Related tax		(2,204	)		—			—			(2,204	)		(3,801	)		61			—			(3,740	)
			3,462			—			—			3,462			5,969			(94	)		—			5,875
	Ending balance	$	(117	)	$	1,935		$	(5,152	)	$	(3,334	)	$	(117	)	$	1,935		$	(5,152	)	$	(3,334	)

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2014
Aggregate Purchase Cost Allocations	'
	The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values:
		Six months ended
		June 30, 2014
	Tangible assets, principally leasehold improvements and equipment, net of cash	$	858
	Amortizable intangible and other long-term assets		69,366
	Goodwill		42,374
	Aggregate purchase price	$	112,598
Reconciliation of Changes in Contingent Earn-Out Obligations	'
	The following is a reconciliation of changes in the contingent earn-out obligations for the six months ended June 30, 2014:
	Beginning balance, January 1, 2014	$	28,058
	Contingent earn-out obligations associated with acquisitions		13,772
	Remeasurement of fair value for other contingent earn-outs		(1,969	)
	Payments of contingent earn-outs		(1,526	)
		$	38,335

Fair_value_of_financial_instru1

Fair value of financial instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis	'
	The following table summarizes the Company’s assets, liabilities and temporary equity measured at fair value on a recurring basis as of June 30, 2014:
		Total		Quoted prices in		Significant other		Significant
				active markets for		observable inputs		unobservable
				identical assets		(Level 2)		inputs
				(Level 1)				(Level 3)
	Assets
	Available-for-sale securities	$	25,685	$	25,685	$	—	$	—
	Interest rate cap agreements	$	2,692	$	—	$	2,692	$	—
	Interest rate swap agreements	$	3,545	$	—	$	3,545	$	—
	Funds on deposit with third parties	$	72,575	$	72,575	$	—	$	—
	Liabilities
	Contingent earn-out obligations	$	38,335	$	—	$	—	$	38,335
	Interest rate swap agreements	$	2,696	$	—	$	2,696	$	—
	Temporary equity
	Noncontrolling interests subject to put provisions	$	760,242	$	—	$	—	$	760,242

Segment_reporting_Tables

Segment reporting (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes	'
	The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
			Three months ended						Six months ended
			June 30,						June 30,
			2014			2013			2014			2013
	Segment net revenues:
	U.S. dialysis and related lab services
	Patient service revenues:
	External sources		$	2,096,605		$	1,980,267		$	4,125,349		$	3,889,050
	Intersegment revenues			9,084			8,158			16,916			15,669
	Total dialysis and related lab services revenues			2,105,689			1,988,425			4,142,265			3,904,719
	Less: Provision for uncollectible accounts			(84,227	)		(69,585	)		(165,690	)		(136,656	)
	Net dialysis and related lab services patient service revenues			2,021,462			1,918,840			3,976,575			3,768,063
	Other revenues(1)			3,579			3,424			6,732			6,319
	Total net dialysis and related lab services revenues			2,025,041			1,922,264			3,983,307			3,774,382
	HCP
	HCP revenues:
	Capitated revenues			783,182			692,357			1,554,724			1,438,428
	Net patient service revenues			58,076			49,433			114,297			103,035
	Other revenues(2)			46,029			19,216			58,553			23,302
	Intersegment capitated and other revenues			204			—			357			—
	Total revenues			887,491			761,006			1,727,931			1,564,765
	Other—Ancillary services and strategic initiatives
	Net patient service revenues—U.S.			4,709			3,050			8,862			6,490
	Net patient service revenues—International			24,035			13,294			47,281			24,357
	Capitated revenues			16,187			17,717			32,210			34,261
	Other external sources—U.S.			222,716			160,988			429,671			309,745
	Other external sources—International			1,598			1,512			3,276			2,924
	Intersegment revenues			4,474			3,397			9,293			6,176
	Total ancillary services and strategic initiatives revenues			273,719			199,958			530,593			383,953
	Total net segment revenues			3,186,251			2,883,228			6,241,831			5,723,100
	Elimination of intersegment revenues			(13,762	)		(11,555	)		(26,566	)		(21,845	)
	Consolidated net revenues		$	3,172,489		$	2,871,673		$	6,215,265		$	5,701,255
	Segment operating margin (loss):
	U.S. dialysis and related lab services		$	407,948		$	401,415		$	794,648		$	486,228
	HCP			82,048			81,382			136,002			189,466
	Other—Ancillary services and strategic initiatives			(1,920	)		(6,791	)		(243	)		(21,392	)
	Total segment margin			488,076			476,006			930,407			654,302
	Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
	Contingent earn-out obligation adjustment			—			56,977			—			56,977
	Corporate support expenses			(3,781	)		(10,963	)		(4,887	)		(22,398	)
	Consolidated operating income			484,295			522,020			925,520			688,881
	Debt expense			(106,132	)		(108,096	)		(212,467	)		(213,913	)
	Debt refinancing charges			(97,548	)		—			(97,548	)		—
	Other income (loss)			1,693			(1,374	)		3,391			(776	)
	Consolidated income from continuing operations before income taxes		$	282,308		$	412,550		$	618,896		$	474,192
	(1)	Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.
	(2)	Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.
Summary of Assets by Segment	'
	Summary of assets by segment is as follows:
			June 30,			December 31,
			2014			2013
	Segment assets
	U.S. dialysis and related lab services		$	10,876,860		$	10,248,993
	HCP			6,369,644			6,265,767
	Other—Ancillary services and strategic initiatives			679,067			584,117
	Consolidated assets		$	17,925,571		$	17,098,877

Changes_in_DaVita_HealthCare_P1

Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries (Tables)	6 Months Ended
	Jun. 30, 2014
Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity	'
	The effects of changes in DaVita HealthCare Partners Inc.’s ownership interest on the Company’s equity are as follows:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014		2013
	Net income attributable to DaVita HealthCare Partners Inc.	$	147,683		$	254,376		$	330,972	$	284,540
	(Decrease) increase in paid-in capital for sales of noncontrolling interests		(66	)		(78	)		15		(887	)
	Increase (decrease) in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest		1,247			(474	)		1,457		(474	)
	Net transfers to noncontrolling interests		1,181			(552	)		1,472		(1,361	)
	Change from net income attributable to DaVita HealthCare Partners Inc. and transfers to noncontrolling interests	$	148,864		$	253,824		$	332,444	$	283,179

Supplemental_data_Tables

Supplemental data (Tables)	6 Months Ended
	Jun. 30, 2014
Condensed Consolidating Statements of Income	'
	Condensed Consolidating Statements of Income
	For the three months ended June 30, 2014		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Patient service revenues		$	—		$	1,517,268		$	668,312		$	1,669		$	2,187,249
	Less: Provision for uncollectible accounts			—			(57,281	)		(30,771	)		—			(88,052	)
	Net patient service revenues			—			1,459,987			637,541			1,669			2,099,197
	Capitated revenues			—			414,366			385,030			(27	)		799,369
	Other revenues			181,199			424,755			35,712			(367,743	)		273,923
	Total net revenues			181,199			2,299,108			1,058,283			(366,101	)		3,172,489
	Operating expenses			122,815			2,033,828			897,652			(366,101	)		2,688,194
	Operating income			58,384			265,280			160,631			—			484,295
	Debt expense, including debt refinancing charges			(202,258	)		(94,169	)		(10,180	)		102,927			(203,680	)
	Other income (expense)			99,532			4,166			922			(102,927	)		1,693
	Income tax (benefit) expense			(17,958	)		111,415			7,430			—			100,887
	Equity earnings in subsidiaries			174,067			110,205			—			(284,272	)		—
	Net income			147,683			174,067			143,943			(284,272	)		181,421
	Less: Net income attributable to noncontrolling interests			—			—			—			(33,738	)		(33,738	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	147,683		$	174,067		$	143,943		$	(318,010	)	$	147,683
	For the three months ended June 30, 2013		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Patient service revenues		$	—		$	1,476,135		$	581,208		$	(8,692	)	$	2,048,651
	Less: Provision for uncollectible accounts			—			(37,218	)		(34,973	)		—			(72,191	)
	Net patient service revenues			—			1,438,917			546,235			(8,692	)		1,976,460
	Capitated revenues			—			337,312			374,451			(1,689	)		710,074
	Other revenues			166,650			374,577			21,183			(377,271	)		185,139
	Total net revenues			166,650			2,150,806			941,869			(387,652	)		2,871,673
	Operating expenses			71,881			1,827,141			838,283			(387,652	)		2,349,653
	Operating income			94,769			323,665			103,586			—			522,020
	Debt expense			(107,337	)		(95,600	)		(11,247	)		106,088			(108,096	)
	Other income (expense)			100,947			3,714			53			(106,088	)		(1,374	)
	Income tax expense			29,458			97,729			2,005			—			129,192
	Equity earnings in subsidiaries			195,455			61,405			—			(256,860	)		—
	Net income			254,376			195,455			90,387			(256,860	)		283,358
	Less: Net income attributable to noncontrolling interests			—			—			—			(28,982	)		(28,982	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	254,376		$	195,455		$	90,387		$	(285,842	)	$	254,376
	For the six months ended June 30, 2014		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Patient service revenues		$	—		$	3,030,545		$	1,267,669		$	3,133		$	4,301,347
	Less: Provision for uncollectible accounts			—			(107,160	)		(64,089	)		—			(171,249	)
	Net patient service revenues			—			2,923,385			1,203,580			3,133			4,130,098
	Capitated revenues			—			818,913			768,428			(407	)		1,586,934
	Other revenues			344,242			818,310			68,003			(732,322	)		498,233
	Total net revenues			344,242			4,560,608			2,040,011			(729,596	)		6,215,265
	Operating expenses			235,112			4,014,282			1,769,947			(729,596	)		5,289,745
	Operating income			109,130			546,326			270,064			—			925,520
	Debt expense, including debt refinancing charges			(307,541	)		(188,806	)		(19,932	)		206,264			(310,015	)
	Other income (expense)			199,475			8,935			1,245			(206,264	)		3,391
	Income tax expense			431			215,546			9,761			—			225,738
	Equity earnings in subsidiaries			330,339			179,430			—			(509,769	)		—
	Net income			330,972			330,339			241,616			(509,769	)		393,158
	Less: Net income attributable to noncontrolling interests			—			—			—			(62,186	)		(62,186	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	330,972		$	330,339		$	241,616		$	(571,955	)	$	330,972
	For the six months ended June 30, 2013		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Patient service revenues		$	—		$	2,928,355		$	1,117,866		$	(17,697	)	$	4,028,524
	Less: Provision for uncollectible accounts			—			(101,075	)		(41,173	)		—			(142,248	)
	Net patient service revenues			—			2,827,280			1,076,693			(17,697	)		3,886,276
	Capitated revenues			—			697,336			778,126			(2,773	)		1,472,689
	Other revenues			302,025			733,034			38,840			(731,609	)		342,290
Total net revenues			302,025			4,257,650			1,893,659			(752,079	)		5,701,255
Operating expenses			192,385			3,908,364			1,663,704			(752,079	)		5,012,374
Operating income			109,640			349,286			229,955			—			688,881
Debt expense			(212,668	)		(190,315	)		(21,970	)		211,040			(213,913	)
Other income (expense)			201,168			9,681			(585	)		(211,040	)		(776	)
Income tax expense			34,055			94,517			15,764			—			144,336
Equity earnings in subsidiaries			220,455			127,482			—			(347,937	)		—
Income from continuing operations			284,540			201,617			191,636			(347,937	)		329,856
Discontinued operations			—			—			13,236			—			13,236
Net income			284,540			201,617			204,872			(347,937	)		343,092
Less: Net income attributable to noncontrolling interests			—			—			—			(58,552	)		(58,552	)
Net income attributable to DaVita HealthCare Partners Inc.		$	284,540		$	201,617		$	204,872		$	(406,489	)	$	284,540
Condensed Consolidating Statements of Comprehensive Income	'
	Condensed Consolidating Statements of Comprehensive Income
	For the three months ended June 30, 2014		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Net income		$	147,683		$	174,067		$	143,943		$	(284,272	)	$	181,421
	Other comprehensive income			2,305			—			—			—			2,305
	Total comprehensive income			149,988			174,067			143,943			(284,272	)		183,726
	Less: comprehensive income attributable to the noncontrolling interests			—			—			—			(33,738	)		(33,738	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	149,988		$	174,067		$	143,943		$	(318,010	)	$	149,988
	For the three months ended June 30, 2013
	Net income		$	254,376		$	195,455		$	90,387		$	(256,860	)	$	283,358
	Other comprehensive income			13,407			—			—			—			13,407
	Total comprehensive income			267,783			195,455			90,387			(256,860	)		296,765
	Less: comprehensive income attributable to the noncontrolling interests			—			—			—			(28,982	)		(28,982	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	267,783		$	195,455		$	90,387		$	(285,842	)	$	267,783
	For the six months ended June 30, 2014		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Net income		$	330,972		$	330,339		$	241,616		$	(509,769	)	$	393,158
	Other comprehensive income			3,311			—			—			—			3,311
	Total comprehensive income			334,283			330,339			241,616			(509,769	)		396,469
	Less: comprehensive income attributable to the noncontrolling interests			—			—			—			(62,186	)		(62,186	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	334,283		$	330,339		$	241,616		$	(571,955	)	$	334,283
	For the six months ended June 30, 2013
	Net income		$	284,540		$	201,617		$	204,872		$	(347,937	)	$	343,092
	Other comprehensive income			11,963			—			—			—			11,963
	Total comprehensive income			296,503			201,617			204,872			(347,937	)		355,055
	Less: comprehensive income attributable to the noncontrolling interests			—			—			—			(58,552	)		(58,552	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	296,503		$	201,617		$	204,872		$	(406,489	)	$	296,503
Condensed Consolidating Balance Sheets	'
	Condensed Consolidating Balance Sheets
	As of June 30, 2014		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Cash and cash equivalents		$	1,081,021		$	137,229		$	202,723		$	—		$	1,420,973
	Accounts receivable, net			—			953,474			596,778			—			1,550,252
	Other current assets			83,242			971,776			135,004			—			1,190,022
	Total current assets			1,164,263			2,062,479			934,505			—			4,161,247
	Property and equipment, net			187,939			1,394,182			708,723			—			2,290,844
	Amortizable intangibles, net			92,421			1,867,978			62,476			—			2,022,875
	Investments in subsidiaries			8,784,145			1,589,418			—			(10,373,563	)		—
	Intercompany receivables			3,645,401			—			545,592			(4,190,993	)		—
	Other long-term assets and investments			59,487			62,812			74,263			—			196,562
	Goodwill			—			7,875,336			1,378,707			—			9,254,043
	Total assets		$	13,933,656		$	14,852,205		$	3,704,266		$	(14,564,556	)	$	17,925,571
	Current liabilities			496,066			1,744,652			367,430			—			2,608,148
	Intercompany payables			—			3,115,717			1,075,276			(4,190,993	)		—
	Long-term debt and other long-term liabilities			8,157,874			1,207,691			234,791			—			9,600,356
	Noncontrolling interests subject to put provisions			493,945			—			—			266,297			760,242
	Total DaVita HealthCare Partners Inc. shareholders’ equity			4,785,771			8,784,145			1,589,418			(10,373,563	)		4,785,771
	Noncontrolling interests not subject to put provisions			—			—			437,351			(266,297	)		171,054
	Total equity			4,785,771			8,784,145			2,026,769			(10,639,860	)		4,956,825
	Total liabilities and equity		$	13,933,656		$	14,852,205		$	3,704,266		$	(14,564,556	)	$	17,925,571
	As of December 31, 2013		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Cash and cash equivalents		$	602,188		$	175,004		$	169,057		$	—		$	946,249
	Accounts receivable, net			—			939,543			545,620			—			1,485,163
	Other current assets			27,910			908,010			104,946			—			1,040,866
	Total current assets			630,098			2,022,557			819,623			—			3,472,278
	Property and equipment, net			177,633			1,377,924			633,854			—			2,189,411
	Amortizable intangibles, net			77,531			1,882,685			64,157			—			2,024,373
	Investments in subsidiaries			8,231,059			1,389,558			—			(9,620,617	)		—
	Intercompany receivables			3,983,214			—			480,993			(4,464,207	)		—
	Other long-term assets and investments			61,391			67,402			71,048			—			199,841
	Goodwill			—			7,837,421			1,375,553			—			9,212,974
	Total assets		$	13,160,926		$	14,577,547		$	3,445,228		$	(14,084,824	)	$	17,098,877
	Current liabilities		$	328,875		$	1,774,634		$	358,540		$	—		$	2,462,049
	Intercompany payables			—			3,421,198			1,043,009			(4,464,207	)		—
	Long-term debt and other long-term liabilities			7,948,390			1,150,656			234,941			—			9,333,987
	Noncontrolling interests subject to put provisions			451,182			—			—			246,118			697,300
	Total DaVita HealthCare Partners Inc. shareholders’ equity			4,432,479			8,231,059			1,389,558			(9,620,617	)		4,432,479
	Noncontrolling interests not subject to put provisions			—			—			419,180			(246,118	)		173,062
	Total equity			4,432,479			8,231,059			1,808,738			(9,866,735	)		4,605,541
	Total liabilities and equity		$	13,160,926		$	14,577,547		$	3,445,228		$	(14,084,824	)	$	17,098,877
Condensed Consolidating Statements of Cash Flows	'
	Condensed Consolidating Statements of Cash Flows
	For the six months ended June 30, 2014		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Cash flows from operating activities:
	Net income		$	330,972		$	330,339		$	241,616		$	(509,769	)	$	393,158
	Changes in operating assets and liabilities and non-cash items included in net income			(191,299	)		7,007			(37,137	)		509,769			288,340
	Net cash provided by operating activities			139,673			337,346			204,479			—			681,498
	Cash flows from investing activities:
	Additions of property and equipment, net			(25,377	)		(123,519	)		(129,697	)		—			(278,593	)
	Acquisitions			—			(97,057	)		(1,385	)		—			(98,442	)
	Proceeds from asset and business sales			—			215			—			—			215
	Purchases/proceeds from investment sales and other items			(58,496	)		(5,263	)		(2,276	)		—			(66,035	)
	Net cash used in investing activities			(83,873	)		(225,624	)		(133,358	)		—			(442,855	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			353,406			(7,158	)		2,188			—			348,436
	Intercompany borrowing			139,052			(137,529	)		(1,523	)		—			—
	Other items			(69,425	)		(4,810	)		(37,553	)		—			(111,788	)
	Net cash provided by (used in) financing activities			423,033			(149,497	)		(36,888	)		—			236,648
	Effect of exchange rate changes on cash			—			—			(567	)		—			(567	)
	Net increase (decrease) in cash and cash equivalents			478,833			(37,775	)		33,666			—			474,724
	Cash and cash equivalents at beginning of period			602,188			175,004			169,057			—			946,249
	Cash and cash equivalents at end of period		$	1,081,021		$	137,229		$	202,723		$	—		$	1,420,973
	For the six months ended June 30, 2013		DaVita			Guarantor			Non-Guarantor			Consolidating			Consolidated
			HealthCare			subsidiaries			subsidiaries			adjustments			total
			Partners Inc.
	Cash flows from operating activities:
	Net income		$	284,540		$	201,617		$	204,872		$	(347,937	)	$	343,092
	Changes in operating assets and liabilities and non-cash items included in net income			(271,776	)		288,254			(21,481	)		347,937			342,934
	Net cash provided by operating activities			12,764			489,871			183,391			—			686,026
	Cash flows from investing activities:
	Additions of property and equipment, net			(24,213	)		(131,671	)		(102,512	)		—			(258,396	)
	Acquisitions			—			(119,818	)		(32,294	)		—			(152,112	)
	Proceeds from asset sales			60,650			3,713			—			—			64,363
	Purchases of investments and other items			(2,201	)		359			100			—			(1,742	)
	Net cash provided by (used in) investing activities			34,236			(247,417	)		(134,706	)		—			(347,887	)
	Cash flows from financing activities:
	Long-term debt and related financing costs, net			(238,400	)		(5,496	)		(7,472	)		—			(251,368	)
	Intercompany borrowing			250,330			(284,739	)		34,409			—			—
	Other items			37,264			5,429			(45,074	)		—			(2,381	)
	Net cash provided by (used in) financing activities			49,194			(284,806	)		(18,137	)		—			(253,749	)
	Effect of exchange rate changes on cash			—			—			(234	)		—			(234	)
	Net increase (decrease) in cash and cash equivalents			96,194			(42,352	)		30,314			—			84,156
	Cash and cash equivalents at beginning of period			195,037			166,107			172,604			—			533,748
	Cash and cash equivalents at end of period		$	291,231		$	123,755		$	202,918		$	—		$	617,904
Reportable Legal Entities	'
Condensed Consolidating Statements of Income	'
	Condensed Consolidating Statements of Income
	For the three months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Patient service operating revenues		$	2,187,249		$	29,361		$	—		$	2,157,888
	Less: Provision for uncollectible accounts			(88,052	)		(1,979	)		—			(86,073	)
	Net patient service operating revenues			2,099,197			27,382			—			2,071,815
	Capitated revenues			799,369			368,551			—			430,818
	Other revenues			273,923			2,313			—			271,610
	Total net operating revenues			3,172,489			398,246			—			2,774,243
	Operating expenses			2,688,194			386,281			(16	)		2,301,929
	Operating income			484,295			11,965			16			472,314
	Debt expense, including refinancing charges			(203,680	)		(3,423	)		—			(200,257	)
	Other income			1,693			25			—			1,668
	Income tax expense			100,887			2,712			7			98,168
	Net income			181,421			5,855			9			175,557
	Minority interests			(33,738	)		—			—			(33,738	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	147,683		$	5,855		$	9		$	141,819
	For the six months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Patient service operating revenues		$	4,301,347		$	60,500		$	—		$	4,240,847
	Less: Provision for uncollectible accounts			(171,249	)		(2,589	)		—			(168,660	)
	Net patient service operating revenues			4,130,098			57,911			—			4,072,187
	Capitated revenues			1,586,934			734,680			—			852,254
	Other revenues			498,233			2,879			—			495,354
	Total net operating revenues			6,215,265			795,470			—			5,419,795
	Operating expenses			5,289,745			775,799			236			4,513,710
	Operating income			925,520			19,671			(236	)		906,085
	Debt expense, including refinancing charges			(310,015	)		(6,618	)		—			(303,397	)
	Other income			3,391			33			—			3,358
	Income tax expense			225,738			4,157			(94	)		221,675
	Net income			393,158			8,929			(142	)		384,371
	Minority interests			(62,186	)		—			—			(62,186	)
	Net income attributable to DaVita HealthCare Partners Inc.		$	330,972		$	8,929		$	(142	)	$	322,185
	(1)	After the elimination of the unrestricted subsidiaries and the physician groups
Condensed Consolidating Statements of Comprehensive Income	'
	Condensed Consolidating Statements of Comprehensive Income
	For the three months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Net income		$	181,421		$	5,855		$	9		$	175,557
	Other comprehensive income			2,305			—			—			2,305
	Total comprehensive income			183,726			5,855			9			177,862
	Less: comprehensive income attributable to the noncontrolling interests			(33,738	)		—			—			(33,738	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	149,988		$	5,855		$	9		$	144,124
	For the six months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Net income		$	393,158		$	8,929		$	(142	)	$	384,371
	Other comprehensive income			3,311			—			—			3,311
	Total comprehensive income			396,469			8,929			(142	)		387,682
	Less: comprehensive income attributable to the noncontrolling interests			(62,186	)		—			—			(62,186	)
	Comprehensive income attributable to DaVita HealthCare Partners Inc.		$	334,283		$	8,929		$	(142	)	$	325,496
	(1)	After the elimination of the unrestricted subsidiaries and the physician groups
Condensed Consolidating Balance Sheets	'
	Condensed Consolidating Balance Sheets
	As of June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Cash and cash equivalents		$	1,420,973		$	117,313		$	—		$	1,303,660
	Accounts receivable, net			1,550,252			239,428			—			1,310,824
	Other current assets			1,190,022			27,776			—			1,162,246
	Total current assets			4,161,247			384,517			—			3,776,730
	Property and equipment, net			2,290,844			5,006			—			2,285,838
	Amortizable intangibles, net			2,022,875			6,794			—			2,016,081
	Other long-term assets			196,562			69,311			3,089			124,162
	Goodwill			9,254,043			9,181			—			9,244,862
	Total assets		$	17,925,571		$	474,809		$	3,089		$	17,447,673
	Current liabilities		$	2,608,148		$	175,238		$	—		$	2,432,910
	Payables to parent			—			202,448			3,089			(205,537	)
	Long-term debt and other long-term liabilities			9,600,356			83,106			—			9,517,250
	Noncontrolling interests subject to put provisions			760,242			—			—			760,242
	Total DaVita HealthCare Partners Inc. shareholders’ equity			4,785,771			14,017			—			4,771,754
	Noncontrolling interests not subject to put provisions			171,054			—			—			171,054
	Shareholders’ equity			4,956,825			14,017			—			4,942,808
	Total liabilities and shareholder’s equity		$	17,925,571		$	474,809		$	3,089		$	17,447,673
	As of December 31, 2013		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Cash and cash equivalents		$	946,249		$	127,309		$	—		$	818,940
	Accounts receivable, net			1,485,163			235,463			—			1,249,700
	Other current assets			1,040,866			35,640			—			1,005,226
	Total current assets			3,472,278			398,412			—			3,073,866
	Property and equipment, net			2,189,411			5,541			—			2,183,870
	Amortizable intangibles, net			2,024,373			7,283			—			2,017,090
	Other long-term assets			199,841			64,013			3,325			132,503
	Goodwill			9,212,974			8,981			—			9,203,993
	Total assets		$	17,098,877		$	484,230		$	3,325		$	16,611,322
	Current liabilities		$	2,462,049		$	193,079		$	—		$	2,268,970
	Payables to parent			—			194,958			3,325			(198,283	)
	Long-term debt and other long-term liabilities			9,333,987			94,727			—			9,239,260
	Noncontrolling interests subject to put provisions			697,300			—			—			697,300
	Total DaVita HealthCare Partners Inc. shareholders’ equity			4,432,479			1,466			—			4,431,013
	Noncontrolling interests not subject to put provisions			173,062			—			—			173,062
	Shareholders’ equity			4,605,541			1,466			—			4,604,075
	Total liabilities and shareholder’s equity		$	17,098,877		$	484,230		$	3,325		$	16,611,322
	(1)	After the elimination of the unrestricted subsidiaries and the physician groups
Condensed Consolidating Statements of Cash Flows	'
	Condensed Consolidating Statements of Cash Flows
	For the six months ended June 30, 2014		Consolidated			Physician			Unrestricted			Company and
			Total			Groups			Subsidiaries			Restricted
												Subsidiaries(1)
	Cash flows from operating activities:
	Net income		$	393,158		$	8,929		$	(142	)	$	384,371
	Changes in operating and intercompany assets and liabilities and non-cash items included in net income			288,340			(27,961	)		142			316,159
	Net cash provided by (used in) operating activities			681,498			(19,032	)		—			700,530
	Cash flows from investing activities:
	Additions of property and equipment			(278,593	)		(20	)		—			(278,573	)
	Acquisitions and divestitures, net			(98,442	)		—			—			(98,442	)
	Proceeds from discontinued operations			215			—			—			215
	Investments and other items			(66,035	)		(2,276	)		—			(63,759	)
	Net cash used in investing activities			(442,855	)		(2,296	)		—			(440,559	)
	Cash flows from financing activities:
	Long-term debt			348,436			—			—			348,436
	Intercompany			—			11,332			—			(11,332	)
	Other items			(111,788	)		—			—			(111,788	)
	Net cash provided by financing activities			236,648			11,332			—			225,316
	Effect of exchange rate changes on cash			(567	)		—			—			(567	)
	Net increase (decrease) in cash			474,724			(9,996	)		—			484,720
	Cash at beginning of year			946,249			127,309			—			818,940
	Cash at end of year		$	1,420,973		$	117,313		$	—		$	1,303,660
	(1)	After the elimination of the unrestricted subsidiaries and the physician groups

Reconciliations_of_Numerators_

Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended				6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Basic:	'		'		'		'
Income from continuing operations attributable to DaVita HealthCare Partners Inc.	$147,683		$254,376		$330,972		$271,291
Increase in noncontrolling interests redemption rights in excess of fair value	'		-259		'		-259
Income from continuing operations for basic earnings per share calculation	147,683		254,117		330,972		271,032
Discontinued operations attributable to DaVita HealthCare Partners Inc.	'		'		'		13,249
Net income attributable to DaVita HealthCare Partners Inc. for basic earnings per share calculation	147,683		254,117		330,972		284,281
Weighted average shares outstanding during the period	214,451,000		211,986,000		214,010,000		211,574,000
Vested stock units	2,000		5,000		2,000		5,000
Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger	-2,194,000		-2,194,000		-2,194,000		-2,194,000
Weighted average shares for basic earnings per share calculation	212,258,994		209,797,334		211,817,893		209,385,380
Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.70		$1.21		$1.56		$1.29
Basic income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.	'		'		'		$0.07
Basic net income per share attributable to DaVita HealthCare Partners Inc.	$0.70		$1.21		$1.56		$1.36
Diluted:	'		'		'		'
Income from continuing operations attributable to DaVita HealthCare Partners Inc.	147,683		254,376		330,972		271,291
Increase in noncontrolling interests redemption rights in excess of fair value	'		-259		'		-259
Income from continuing operations for diluted earnings per share calculation	147,683		254,117		330,972		271,032
Discontinued operations attributable to DaVita HealthCare Partners Inc.	'		'		'		13,249
Net income attributable to DaVita HealthCare Partners Inc. for diluted earnings per share calculation	$147,683		$254,117		$330,972		$284,281
Weighted average shares outstanding during the period	214,451,000		211,986,000		214,010,000		211,574,000
Vested stock units	2,000		5,000		2,000		5,000
Assumed incremental shares from stock plans	2,268,000		2,858,000		2,409,000		2,911,000
Weighted average shares for diluted earnings per share calculation	216,720,944		214,849,164		216,420,713		214,490,452
Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.	$0.68		$1.18		$1.53		$1.26
Diluted income from discontinued operations per share attributable to DaVita HealthCare Partners Inc.	'		'		'		$0.07
Diluted net income per share attributable to DaVita HealthCare Partners Inc.	$0.68		$1.18		$1.53		$1.33
Anti-dilutive stock-settled awards excluded from calculation	990,000	[1]	4,520,000	[1]	1,995,000	[1]	3,353,000	[1]
[1]	Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts_Receivable_Additional

Accounts Receivable - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Percentage of outstanding patient accounts receivables to be reserved as per Company's policy	100.00%
Account receivable outstanding, number of months	'4 months
Increased in allowance for doubtful accounts	$7,735
Government-based Programs, Medicare and Medicaid | Accounts Receivable	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Percentage of accounts receivable due	80.00%
Health Care Patient | Accounts Receivable	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Percentage of accounts receivable due	1.00%

Investments_Detail

Investments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Certificates of deposit and money market funds due within one year	$62,374	$5,601
Investments in mutual funds and common stock	25,685	19,421
Total investment	88,059	25,022
Short-term investments	63,835	6,801
Long-term investments	24,224	18,221
Total investment	88,059	25,022
Held to maturity	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Certificates of deposit and money market funds due within one year	62,374	5,601
Total investment	62,374	5,601
Short-term investments	62,374	5,601
Total investment	62,374	5,601
Available for sale	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Investments in mutual funds and common stock	25,685	19,421
Total investment	25,685	19,421
Short-term investments	1,461	1,200
Long-term investments	24,224	18,221
Total investment	$25,685	$19,421

Recovered_Sheet1

Investments in Debt and Equity Securities and Other Investments - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'	'
Available for sale investments gross pre-tax unrealized gain (loss)	$6,161	'	$6,161	'	$5,096
Unrealized gain (loss) on investments, pre tax	'	'	1,405	'	'
Unrealized gain (loss) on investments, net of tax	578	101	909	719	'
Proceeds from sale of investments available for sale	'	'	1,277	1,091	'
Pre tax reclassification of net investment realized gain (loss) into net income	'	'	340	155	'
Reclassification of net investment realized gain (loss) into net income, net of tax	'	'	207	94	'
Preferred Stock	'	'	'	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'	'
Preferred stock, in a privately held company	5,000	'	5,000	'	'
HealthCare Partners (HCP)	'	'	'	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'	'
Required minimum cash balance	$58,000	'	$58,000	'	'

Changes_in_Goodwill_by_Reporta

Changes in Goodwill by Reportable Segments (Detail) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Goodwill [Line Items]	'	'
Beginning balance	$9,212,974	$8,952,750
Acquisitions	42,374	271,267
Divestitures	'	-2,728
Other adjustments	-1,305	-8,315
Ending balance	9,254,043	9,212,974
U.S. dialysis and related lab services	'	'
Goodwill [Line Items]	'	'
Beginning balance	5,469,473	5,309,152
Acquisitions	2,915	163,037
Divestitures	'	-2,728
Other adjustments	'	12
Ending balance	5,472,388	5,469,473
HealthCare Partners (HCP)	'	'
Goodwill [Line Items]	'	'
Beginning balance	3,516,162	3,506,571
Acquisitions	38,639	17,833
Other adjustments	-2,277	-8,242
Ending balance	3,552,524	3,516,162
Other-Ancillary services and strategic initiatives	'	'
Goodwill [Line Items]	'	'
Beginning balance	227,339	137,027
Acquisitions	820	90,397
Other adjustments	972	-85
Ending balance	$229,131	$227,339

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'	'
Goodwill	$9,254,043	$9,212,974	$8,952,750
Goodwill impairment charge description	'For example, a sustained, long-term reduction of 3% in operating income for HCP California and HCP Nevada could reduce their estimated fair values by up to 3.1% and 2.9%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California and HCP Nevada by up to 7.7% and 6.1%, respectively.	'	'
Pre-tax goodwill impairment charge	0	'	'
HealthCare Partners (HCP)	'	'	'
Goodwill [Line Items]	'	'	'
Number of reporting units	2	'	'
Goodwill	3,552,524	3,516,162	3,506,571
HealthCare Partners (HCP) | California	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill	2,511,477	'	'
Percentage of Fair value in excess of carrying amoung	6.00%	'	'
HealthCare Partners (HCP) | Nevada	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill	$517,618	'	'
Percentage of Fair value in excess of carrying amoung	10.90%	'	'

Components_of_Changes_in_Healt

Components of Changes in Health Care Costs Payable (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
In Thousands, unless otherwise specified			Healthcare Cost
Medical Expense And Medical Claims Payable [Line Items]	'	'	'
Health care costs payable, beginning of the period	$304,551	$287,452	$172,310
Add: Components of incurred health care costs	'	'	'
Current year	'	'	775,604
Prior years	'	'	5,602
Total incurred health care costs	'	'	781,206
Less: Claims paid	'	'	'
Current year	'	'	589,968
Prior years	'	'	153,223
Total claims paid	'	'	743,191
Health care costs payable, end of the period	$304,551	$287,452	$210,325

Health_Care_Costs_Payable_Addi

Health Care Costs Payable - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Medical Expense And Medical Claims Payable [Line Items]	'
Increase in prior year estimates of health care costs payable	$5,602

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Income Taxes [Line Items]	'	'
Total unrecognized tax benefits that would affect effective tax rate, if recognized	$32,945	'
Decrease in liability for unrecognized tax benefits	-166	'
Liability for unrecognized tax benefits	60,372	60,538
Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits	11,969	10,742
Unrecognized tax benefits that may be recognized within the next 12 months	$27,427	'

Long_Term_Debt_Detail

Long Term Debt (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Senior notes	$4,066,907	$2,800,000
Acquisition obligations and other notes payable	66,511	67,352
Capital lease obligations	183,647	152,751
Total debt principal outstanding	8,817,065	8,433,603
Discount on long-term debt	-17,500	-17,675
Carrying Amount of Long-Term Debt, Net of Unamortized Discount or Premium, Current and Noncurrent, Total	8,799,565	8,415,928
Less current portion	-408,987	-274,697
Long Term Debt and Capital Lease Obligations Noncurrent	8,390,578	8,141,231
Carrying Amount of Long-Term Debt, Net of Unamortized Discount or Premium, Current and Noncurrent, Total	8,799,565	8,415,928
New Term Loan A	'	'
Debt Instrument [Line Items]	'	'
Senior Secured Credit Facilities	1,000,000	'
New Term Loan B	'	'
Debt Instrument [Line Items]	'	'
Senior Secured Credit Facilities	3,500,000	'
Prior Term Loan A	'	'
Debt Instrument [Line Items]	'	'
Senior Secured Credit Facilities	'	800,000
Prior Term Loan A-3	'	'
Debt Instrument [Line Items]	'	'
Senior Secured Credit Facilities	'	1,282,500
Prior Term Loan B	'	'
Debt Instrument [Line Items]	'	'
Senior Secured Credit Facilities	'	1,697,500
Prior Term Loan B-2	'	'
Debt Instrument [Line Items]	'	'
Senior Secured Credit Facilities	'	$1,633,500

Classification_of_Long_Term_De

Classification of Long Term Debt (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Senior notes	$291,907	'
Current portion	117,080	274,697
Total current portion	408,987	274,697
Long-term debt	8,390,578	8,141,231
Carrying Amount of Long-Term Debt, Net of Unamortized Discount or Premium, Current and Noncurrent, Total	$8,799,565	$8,415,928

Scheduled_Maturities_of_Longte

Scheduled Maturities of Long-term Debt (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'
2014 (remainder of the year, including the 6 3/8% Senior Notes)	$347,712
2015	112,182
2016	115,645
2017	141,972
2018	153,282
2019	727,238
Thereafter	$7,219,034

Scheduled_Maturities_of_Longte1

Scheduled Maturities of Long-term Debt (Parenthetical) (Detail)	Jun. 30, 2014
Debt Instrument [Line Items]	'
Senior note, interest rate	6.38%

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

In Thousands, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Maximum

Amortizing Swap

Interest rate swap agreements

HealthCare Partners (HCP)

Prior Term Loan A

Term Loan A-3

Prior Term Loan B

Prior Term Loan B

Prior Term Loan B

Prior Term Loan B

Prior Term Loan B

Prior Term Loan B-2

New Term Loan A

New Term Loan A

New Term Loan A

New Term Loan A

New Term Loan A

New Term Loan A

New Term Loan A

New Credit Agreement

Revolving Credit Facility

New Term Loan A

New Term Loan B

New Term Loan B

New Term Loan B

Senior Notes 5.125 Percent Due 2024

Senior Notes 5.125 Percent Due 2024

Senior Notes 5.125 Percent Due 2024

New Term Loans and Senior Notes 5.125 Percent Due 2024

New Term Loans

Senior Secured Credit Facilities

Senior Notes 6.375 Percent Due 2018

Senior Notes 6.375 Percent Due 2018

Senior Notes 6.375 Percent Due 2018

New Term Loan B

New Term Loan B

New Term Loan A

Interest rate cap agreements

Interest rate cap agreements

Interest rate cap agreements

Interest rate cap agreements

Interest rate swap agreements

Interest rate swap agreements

London Interbank Offered Rate (LIBOR)

London Interbank Offered Rate (LIBOR)

London Interbank Offered Rate (LIBOR)

London Interbank Offered Rate (LIBOR)

Maximum

London Interbank Offered Rate (LIBOR)

Maximum

Subsequent Event

Subsequent Event

London Interbank Offered Rate (LIBOR)

London Interbank Offered Rate (LIBOR)

Derivative Instrument 1

Derivative Instrument 1

Derivative Instrument 2

Derivative Instrument 2

Unhedged

Maximum

Minimum

Interest rate swap agreements

Debt Instrument, Redemption, Period One

Debt Instrument, Redemption, Period Two

Maximum

Contract

Maximum

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument principal payment

'

'

'

'

'

'

'

'

'

$37,500

$16,875

$4,375

'

'

'

'

$4,125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Facility, aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

1,000,000

'

'

'

'

'

'

5,500,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Facility, term

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum additional borrowing capacity

1,500,000

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior secured leverage ratio

'

'

'

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

2.00%

1.50%

1.75%

'

'

'

'

'

2.75%

'

'

'

'

'

'

'

'

'

'

2.75%

1.75%

Long term borrowing annual principal payment, 2014

347,712

'

347,712

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

17,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2015

112,182

'

112,182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2016

115,645

'

115,645

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

62,500

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2017

141,972

'

141,972

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87,500

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2018

153,282

'

153,282

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2019

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

675,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument interest LIBOR rate

'

'

'

'

'

'

'

'

'

'

'

'

'

2.50%

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

0.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2019

727,238

'

727,238

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term borrowing annual principal payment, 2021

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,272,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Covenants factor leverage ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior note

4,066,907

'

4,066,907

'

2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,750,000

1,750,000

'

'

'

'

'

'

'

'

'

'

Senior note, interest rate

6.38%

'

6.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.13%

5.13%

'

'

'

'

'

'

'

'

'

'

Senior note, due date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2024

'

'

'

'

'

'

'

'

'

'

'

Senior notes interest payment period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The 5 1/8% Senior Notes pay interest on January 15 and July 15 of each year beginning January 15, 2015.

'

'

'

'

'

'

'

'

'

'

'

Senior notes interest payment, first required payment date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Jan-15

'

'

'

'

'

'

'

'

'

'

'

Debt redemption end date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Jul-19

'

15-Jul-17

'

'

'

'

'

'

'

'

'

Percentage of redemption

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

Proceeds from borrowings

'

'

33,136,743

33,445,567

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,750,000

'

6,250,000

4,500,000

'

'

'

'

'

'

'

Payment of total outstanding principal balances under existing Senior Secured Credit Facilities plus accrued interest

'

'

32,788,307

33,696,216

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,362,428

'

'

'

'

'

'

Outstanding principal balances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

483,093

'

'

'

'

'

Aggregate debt principal balances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

775,000

188

291,719

'

'

'

Redemption of total amount of debt including principal and interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

512,386

194

309,954

'

'

'

Debt instrument, redemption price ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,051.25

1,021.25

1,047.81

'

'

'

Cash tender premium for redemption

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,759

4

13,947

'

'

'

Fees, discounts and other professional expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

81,569

'

'

'

'

'

Debt Refinancing Charge

97,548

'

97,548

'

'

'

'

3,140

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount terminated

'

'

'

'

'

'

1,137,500

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of gains (losses) recognized in other comprehensive income on interest rate swap

'

'

2,972

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt expense

106,132

108,096

212,467

213,913

'

'

'

6,137

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate agreements, notional amount

'

'

'

'

'

'

'

'

'

'

'

'

2,735,000

'

1,250,000

'

'

'

878,750

121,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed interest rate, lower limit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.49%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed interest rate, upper limit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.52%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average effective interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.26%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cap agreements, expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Sep-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt expense recognized

'

'

'

'

'

'

'

'

'

'

'

'

1,220

'

1,794

'

'

'

1,592

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of assets

'

'

'

'

'

'

'

'

'

'

'

'

2,692

'

'

'

'

'

849

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrealized pre-tax losses in other comprehensive income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrealized loss in other comprehensive income

-5,209

11,685

-7,714

9,316

'

'

'

'

'

'

'

'

4,874

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of interest rate agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LIBOR interest rate for interest cap

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.50%

'

'

Overall weighted average effective interest rate on Senior Secured Credit Facilities

3.51%

'

3.51%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average effective interest rate

'

'

4.85%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Overall weighted average effective interest rate

4.56%

'

4.56%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Undrawn revolving credit facilities

1,000,000

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding letters of credit

$83,000

'

$83,000

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative_Instruments_Detail

Derivative Instruments (Detail) (Designated as Hedging Instrument, USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Interest rate swap agreements | Other short-term liabilities	'	'
Derivative [Line Items]	'	'
Derivative liabilities, Fair value	$2,696	$12,069
Interest rate swap agreements | Other long-term assets	'	'
Derivative [Line Items]	'	'
Derivative assets, Fair value	3,545	10,004
Interest rate cap agreements | Other long-term assets	'	'
Derivative [Line Items]	'	'
Derivative assets, Fair value	$2,692	$7,567

Effects_of_Interest_Rate_Swap_

Effects of Interest Rate Swap Agreements (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative [Line Items]	'	'	'	'
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	'	'	$2,972	'
Cash Flow Hedging	'	'	'	'
Derivative [Line Items]	'	'	'	'
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	-5,209	11,685	-7,714	9,316
Amount of losses reclassified from accumulated OCI into income	-4,997	-3,462	-8,356	-5,969
Cash Flow Hedging | Interest rate swap agreements	'	'	'	'
Derivative [Line Items]	'	'	'	'
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	-5,022	13,266	-7,786	12,302
Cash Flow Hedging | Interest rate swap agreements | Debt expense (including refinancing charges)	'	'	'	'
Derivative [Line Items]	'	'	'	'
Amount of losses reclassified from accumulated OCI into income	-6,694	-4,159	-10,700	-7,366
Cash Flow Hedging | Interest rate cap agreements	'	'	'	'
Derivative [Line Items]	'	'	'	'
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	-3,527	5,858	-4,874	2,945
Cash Flow Hedging | Interest rate cap agreements | Debt expense (including refinancing charges)	'	'	'	'
Derivative [Line Items]	'	'	'	'
Amount of losses reclassified from accumulated OCI into income	-1,507	-1,507	-3,014	-2,404
Cash Flow Hedging | Tax benefit (expense)	'	'	'	'
Derivative [Line Items]	'	'	'	'
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	3,340	-7,439	4,946	-5,931
Amount of losses reclassified from accumulated OCI into income	$3,204	$2,204	$5,358	$3,801

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (U.S. Attorney Physician Relationship Investigation, USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
U.S. Attorney Physician Relationship Investigation	'
Legal Proceedings [Line Items]	'
Contingency reserve	$397,000
Settlement payment	$389,000

Recovered_Sheet2

Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Commitments and Contingencies Disclosure [Line Items]	'
Other potential commitments to provide operating capital to several dialysis centers	$2,000
Schedule of Joint ventures to dissolve	'Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
Minimum	'
Commitments and Contingencies Disclosure [Line Items]	'
Scheduled dissolution term of joint ventures	'10 years
Maximum	'
Commitments and Contingencies Disclosure [Line Items]	'
Scheduled dissolution term of joint ventures	'50 years

Recovered_Sheet3

Long-term Incentive Compensation - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Long-term incentive program (LTIP) expense	$52,960	$38,773
Stock-based compensation expense	29,699	32,266
Tax benefit from stock-based compensation	10,997	12,171
Unrecognized compensation cost related to outstanding LTIP awards	162,351	'
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans	99,331	'
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under performance-based cash component of LTIP costs, weighted average remaining period (in years)	'1 year 1 month 6 days	'
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)	'1 year 4 months 24 days	'
Tax benefits from stock award exercises	42,110	36,524
Stock Appreciation Rights	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock granted	1,248	'
Stock appreciation, aggregate grant-date fair value	19,997	'
Weighted-average expected life (in years)	'4 years 2 months 12 days	'
Stock Unit	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock granted	316	'
Weighted-average expected life (in years)	'3 years 4 months 24 days	'
Stock units, aggregate grant-date fair value	$22,809	'

Comprehensive_Income_Detail

Comprehensive Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	($2,645)	'
Unrealized (losses) gains	'	'	1,405	'
Unrealized (losses) gains net	578	101	909	719
Reclassification from accumulated other comprehensive income into net income	'	'	-340	-155
Reclassification from accumulated other comprehensive income into net income net of tax	'	'	-207	-94
Ending balance	666	'	666	'
Interest Rate Swaps and Interest Rate Cap Agreements	'	'	'	'
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	-1,490	-15,264	-2,344	-15,402
Unrealized (losses) gains	-8,549	19,124	-12,660	15,247
Related income tax (expense) benefit	3,340	-7,439	4,946	-5,931
Unrealized (losses) gains net	-5,209	11,685	-7,714	9,316
Reclassification from accumulated other comprehensive income into net income	8,201	5,666	13,714	9,770
Related tax	-3,204	-2,204	-5,358	-3,801
Reclassification from accumulated other comprehensive income into net income net of tax	4,997	3,462	8,356	5,969
Ending balance	-1,702	-117	-1,702	-117
Investment securities	'	'	'	'
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	3,244	1,834	3,120	1,310
Unrealized (losses) gains	875	166	1,405	1,178
Related income tax (expense) benefit	-297	-65	-496	-459
Unrealized (losses) gains net	578	101	909	719
Reclassification from accumulated other comprehensive income into net income	'	'	-340	-155
Related tax	'	'	133	61
Reclassification from accumulated other comprehensive income into net income net of tax	'	'	-207	-94
Ending balance	3,822	1,935	3,822	1,935
Foreign currency translation adjustments	'	'	'	'
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	-3,393	-3,311	-3,421	-1,205
Unrealized (losses) gains	1,939	-1,841	1,967	-3,947
Unrealized (losses) gains net	1,939	-1,841	1,967	-3,947
Ending balance	-1,454	-5,152	-1,454	-5,152
Accumulated other comprehensive income (loss)	'	'	'	'
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	-1,639	-16,741	-2,645	-15,297
Unrealized (losses) gains	-5,736	17,449	-9,289	12,478
Related income tax (expense) benefit	3,044	-7,504	4,451	-6,390
Unrealized (losses) gains net	-2,692	9,945	-4,838	6,088
Reclassification from accumulated other comprehensive income into net income	8,201	5,666	13,374	9,615
Related tax	-3,204	-2,204	-5,225	-3,740
Reclassification from accumulated other comprehensive income into net income net of tax	4,997	3,462	8,149	5,875
Ending balance	$666	($3,334)	$666	($3,334)

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Business Acquisition [Line Items]	'	'
Amortizable intangible assets acquired, weighted-average estimated useful lives	'9 years 10 months 24 days	'
Goodwill deductible for tax purposes associated with acquisitions	$27,789	'
Contingent earn-out obligations	38,335	28,058
Other Accrued Liabilities	'	'
Business Acquisition [Line Items]	'	'
Contingent earn-out obligations	13,682	'
Other long-term liabilities	'	'
Business Acquisition [Line Items]	'	'
Contingent earn-out obligations	24,653	'
Other companies	'	'
Business Acquisition [Line Items]	'	'
Additional cash consideration in the form of earn-out payments	136,300	'
Fair value of contingent earn-out consideration	38,335	'
Other companies | Scenario 1	'	'
Business Acquisition [Line Items]	'	'
Earn out consideration payment period	'2 years	'
Other companies | Earn-out obligations	'	'
Business Acquisition [Line Items]	'	'
Earn out consideration payment period	'3 years	'
Other dialysis acquisitions	'	'
Business Acquisition [Line Items]	'	'
Cash paid to acquire business	98,442	'
Deferred purchase price obligations	$14,156	'
Other dialysis acquisitions | U.S. dialysis and related lab services	'	'
Business Acquisition [Line Items]	'	'
Number of businesses acquired	1	'
Other dialysis acquisitions | Foreign Dialysis And Other Medical Businesses	'	'
Business Acquisition [Line Items]	'	'
Number of businesses acquired	3	'

Assets_Acquired_and_Liabilitie

Assets Acquired and Liabilities Assumed and Recognized at Acquisition Dates at Estimated Fair Values (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'	'
Goodwill	$9,254,043	$9,212,974	$8,952,750
U.S. dialysis and related lab services	'	'	'
Business Acquisition [Line Items]	'	'	'
Tangible assets, principally leasehold improvements and equipment, net of cash	858	'	'
Amortizable intangible and other long-term assets	69,366	'	'
Goodwill	42,374	'	'
Aggregate purchase price	$112,598	'	'

Reconciliation_of_Changes_in_C

Reconciliation of Changes in Contingent Earn-Out Obligations (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Business Combination Segment Allocation [Line Items]	'
Beginning balance	$28,058
Contingent earn-out obligations associated with acquisitions	13,772
Remeasurement of fair value	-1,969
Payments of contingent earn-outs	-1,526
Ending balance	$38,335

Variable_Interest_Entities_Add

Variable Interest Entities - Additional Information (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Variable Interest Entity [Line Items]	'
Asset	$515,618
Liabilities	$307,133

Assets_Liabilities_and_Tempora

Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Liabilities	'	'
Contingent earn-out obligations	$38,335	$28,058
Fair Value, Measurements, Recurring	'	'
Assets	'	'
Available-for-sale securities	25,685	'
Funds on deposit with third parties	72,575	'
Liabilities	'	'
Contingent earn-out obligations	38,335	'
Interest rate swap agreements	2,696	'
Temporary equity	'	'
Noncontrolling interests subject to put provisions	760,242	'
Fair Value, Measurements, Recurring | Interest rate cap agreements	'	'
Assets	'	'
Interest rate derivative agreements	2,692	'
Fair Value, Measurements, Recurring | Interest rate swap agreements	'	'
Assets	'	'
Interest rate derivative agreements	3,545	'
Fair Value, Measurements, Recurring | Level 1	'	'
Assets	'	'
Available-for-sale securities	25,685	'
Funds on deposit with third parties	72,575	'
Fair Value, Measurements, Recurring | Level 2	'	'
Liabilities	'	'
Interest rate swap agreements	2,696	'
Fair Value, Measurements, Recurring | Level 2 | Interest rate cap agreements	'	'
Assets	'	'
Interest rate derivative agreements	2,692	'
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap agreements	'	'
Assets	'	'
Interest rate derivative agreements	3,545	'
Fair Value, Measurements, Recurring | Level 3	'	'
Liabilities	'	'
Contingent earn-out obligations	38,335	'
Temporary equity	'	'
Noncontrolling interests subject to put provisions	$760,242	'

Recovered_Sheet4

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Debt instrument, carrying amount	$8,817,065	$8,433,603
Senior Secured Credit Facility	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Debt instrument, carrying amount	4,482,500	'
Debt instrument, fair value	4,526,300	'
Senior Notes	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Debt instrument, carrying amount	4,066,907	'
Debt instrument, fair value	$4,229,200	'

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Number of major lines of business	'	'	2	'
U.S. dialysis and related lab services	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	$99,163	$88,588	$195,606	$173,540
Total amount of expenditures for property and equipment	136,660	128,699	249,869	230,775
HealthCare Partners (HCP)	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	42,260	38,590	83,997	76,607
Total amount of expenditures for property and equipment	5,777	7,840	10,279	14,379
Other-Ancillary services and strategic initiatives	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization expense	4,484	3,411	8,883	6,351
Total amount of expenditures for property and equipment	$9,594	$5,133	$18,445	$13,242

Summary_of_Segment_Net_Revenue

Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Detail) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Segment Reporting Information [Line Items]	'		'		'		'
Patient service revenues	$2,187,249		$2,048,651		$4,301,347		$4,028,524
Net patient service revenues	2,099,197		1,976,460		4,130,098		3,886,276
Other revenues	273,923		185,139		498,233		342,290
Total net operating revenues	3,172,489		2,871,673		6,215,265		5,701,255
Capitated revenues	799,369		710,074		1,586,934		1,472,689
Operating income	484,295		522,020		925,520		688,881
Contingent earn-out obligation adjustment	'		56,977		'		56,977
Corporate support expenses	-3,781		-10,963		-4,887		-22,398
Debt expense	-106,132		-108,096		-212,467		-213,913
Debt refinancing charges	-97,548		'		-97,548		'
Other income (loss)	1,693		-1,374		3,391		-776
Consolidated income from continuing operations before income taxes	282,308		412,550		618,896		474,192
U.S. dialysis and related lab services	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Patient service revenues	2,105,689		1,988,425		4,142,265		3,904,719
Less: Provision for uncollectible accounts	-84,227		-69,585		-165,690		-136,656
Net patient service revenues	2,021,462		1,918,840		3,976,575		3,768,063
Other revenues	3,579	[1]	3,424	[1]	6,732	[1]	6,319	[1]
HealthCare Partners (HCP)	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Net patient service revenues	58,076		49,433		114,297		103,035
Other revenues	46,029	[2]	19,216	[2]	58,553	[2]	23,302	[2]
Capitated revenues	783,182		692,357		1,554,724		1,438,428
Other-Ancillary services and strategic initiatives	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Capitated revenues	16,187		17,717		32,210		34,261
Other-Ancillary services and strategic initiatives | U.S.	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Net patient service revenues	4,709		3,050		8,862		6,490
Other revenues	222,716		160,988		429,671		309,745
Other-Ancillary services and strategic initiatives | International	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Net patient service revenues	24,035		13,294		47,281		24,357
Other revenues	1,598		1,512		3,276		2,924
Operating Segments	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Total net operating revenues	3,186,251		2,883,228		6,241,831		5,723,100
Operating income	488,076		476,006		930,407		654,302
Operating Segments | U.S. dialysis and related lab services	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Patient service revenues	2,096,605		1,980,267		4,125,349		3,889,050
Total net operating revenues	2,025,041		1,922,264		3,983,307		3,774,382
Operating income	407,948		401,415		794,648		486,228
Operating Segments | HealthCare Partners (HCP)	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Total net operating revenues	887,491		761,006		1,727,931		1,564,765
Operating income	82,048		81,382		136,002		189,466
Operating Segments | Other-Ancillary services and strategic initiatives	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Total net operating revenues	273,719		199,958		530,593		383,953
Operating income	-1,920		-6,791		-243		-21,392
Intersegment Elimination	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Total net operating revenues	-13,762		-11,555		-26,566		-21,845
Intersegment Elimination | U.S. dialysis and related lab services	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Patient service revenues	9,084		8,158		16,916		15,669
Intersegment Elimination | HealthCare Partners (HCP)	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Other revenues	204		'		357		'
Intersegment Elimination | Other-Ancillary services and strategic initiatives	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Total net operating revenues	$4,474		$3,397		$9,293		$6,176
[1]	Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.
[2]	Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.

Summary_of_Segment_Net_Revenue1

Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2014
Segment Reporting Information [Line Items]	'
Percentage of ownership in unconsolidated joint ventures	50.00%

Summary_of_Assets_by_Segment_D

Summary of Assets by Segment (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Segment assets	'	'
Total assets	$17,925,571	$17,098,877
U.S. dialysis and related lab services	'	'
Segment assets	'	'
Total assets	10,876,860	10,248,993
HealthCare Partners (HCP)	'	'
Segment assets	'	'
Total assets	6,369,644	6,265,767
Other-Ancillary services and strategic initiatives	'	'
Segment assets	'	'
Total assets	$679,067	$584,117

Effects_of_Changes_in_DaVita_I

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]	'	'	'	'
Net income attributable to DaVita HealthCare Partners Inc.	$147,683	$254,376	$330,972	$284,540
Net transfers to noncontrolling interests	1,181	-552	1,472	-1,361
Change from net income attributable to DaVita HealthCare Partners Inc. and transfers to noncontrolling interests	148,864	253,824	332,444	283,179
Additional paid-in capital	'	'	'	'
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]	'	'	'	'
(Decrease) increase in paid-in capital for sales of noncontrolling interests	-66	-78	15	-887
Increase (decrease) in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest	$1,247	($474)	$1,457	($474)

Condensed_Consolidating_Statem

Condensed Consolidating Statements of Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Patient service revenues	$2,187,249	$2,048,651	$4,301,347	$4,028,524
Less: Provision for uncollectible accounts	-88,052	-72,191	-171,249	-142,248
Net patient service revenues	2,099,197	1,976,460	4,130,098	3,886,276
Capitated revenues	799,369	710,074	1,586,934	1,472,689
Other revenues	273,923	185,139	498,233	342,290
Total net revenues	3,172,489	2,871,673	6,215,265	5,701,255
Operating expenses	2,688,194	2,349,653	5,289,745	5,012,374
Operating income	484,295	522,020	925,520	688,881
Debt expense	-203,680	-108,096	-310,015	-213,913
Other income (expense)	1,693	-1,374	3,391	-776
Income tax (benefit) expense	100,887	129,192	225,738	144,336
Income from continuing operations	181,421	283,358	393,158	329,856
Discontinued operations	'	'	'	13,236
Net income	181,421	283,358	393,158	343,092
Less: Net income attributable to noncontrolling interests	-33,738	-28,982	-62,186	-58,552
Net income	147,683	254,376	330,972	284,540
DaVita HealthCare Partners Inc.	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Other revenues	181,199	166,650	344,242	302,025
Total net revenues	181,199	166,650	344,242	302,025
Operating expenses	122,815	71,881	235,112	192,385
Operating income	58,384	94,769	109,130	109,640
Debt expense	-202,258	-107,337	-307,541	-212,668
Other income (expense)	99,532	100,947	199,475	201,168
Income tax (benefit) expense	-17,958	29,458	431	34,055
Equity earnings in subsidiaries	174,067	195,455	330,339	220,455
Income from continuing operations	'	'	'	284,540
Net income	147,683	254,376	330,972	284,540
Net income	147,683	254,376	330,972	284,540
Guarantor Subsidiaries	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Patient service revenues	1,517,268	1,476,135	3,030,545	2,928,355
Less: Provision for uncollectible accounts	-57,281	-37,218	-107,160	-101,075
Net patient service revenues	1,459,987	1,438,917	2,923,385	2,827,280
Capitated revenues	414,366	337,312	818,913	697,336
Other revenues	424,755	374,577	818,310	733,034
Total net revenues	2,299,108	2,150,806	4,560,608	4,257,650
Operating expenses	2,033,828	1,827,141	4,014,282	3,908,364
Operating income	265,280	323,665	546,326	349,286
Debt expense	-94,169	-95,600	-188,806	-190,315
Other income (expense)	4,166	3,714	8,935	9,681
Income tax (benefit) expense	111,415	97,729	215,546	94,517
Equity earnings in subsidiaries	110,205	61,405	179,430	127,482
Income from continuing operations	'	'	'	201,617
Net income	174,067	195,455	330,339	201,617
Net income	174,067	195,455	330,339	201,617
Non-Guarantor Subsidiaries	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Patient service revenues	668,312	581,208	1,267,669	1,117,866
Less: Provision for uncollectible accounts	-30,771	-34,973	-64,089	-41,173
Net patient service revenues	637,541	546,235	1,203,580	1,076,693
Capitated revenues	385,030	374,451	768,428	778,126
Other revenues	35,712	21,183	68,003	38,840
Total net revenues	1,058,283	941,869	2,040,011	1,893,659
Operating expenses	897,652	838,283	1,769,947	1,663,704
Operating income	160,631	103,586	270,064	229,955
Debt expense	-10,180	-11,247	-19,932	-21,970
Other income (expense)	922	53	1,245	-585
Income tax (benefit) expense	7,430	2,005	9,761	15,764
Income from continuing operations	'	'	'	191,636
Discontinued operations	'	'	'	13,236
Net income	143,943	90,387	241,616	204,872
Net income	143,943	90,387	241,616	204,872
Consolidating Adjustments	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Patient service revenues	1,669	-8,692	3,133	-17,697
Net patient service revenues	1,669	-8,692	3,133	-17,697
Capitated revenues	-27	-1,689	-407	-2,773
Other revenues	-367,743	-377,271	-732,322	-731,609
Total net revenues	-366,101	-387,652	-729,596	-752,079
Operating expenses	-366,101	-387,652	-729,596	-752,079
Debt expense	102,927	106,088	206,264	211,040
Other income (expense)	-102,927	-106,088	-206,264	-211,040
Equity earnings in subsidiaries	-284,272	-256,860	-509,769	-347,937
Income from continuing operations	'	'	'	-347,937
Net income	-284,272	-256,860	-509,769	-347,937
Less: Net income attributable to noncontrolling interests	-33,738	-28,982	-62,186	-58,552
Net income	($318,010)	($285,842)	($571,955)	($406,489)

Condensed_Consolidating_Statem1

Condensed Consolidating Statements of Comprehensive Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income	$181,421	$283,358	$393,158	$343,092
Other comprehensive income	2,305	13,407	3,311	11,963
Total comprehensive income	183,726	296,765	396,469	355,055
Less: Comprehensive income attributable to noncontrolling interests	-33,738	-28,982	-62,186	-58,552
Comprehensive income attributable to DaVita HealthCare Partners Inc.	149,988	267,783	334,283	296,503
DaVita HealthCare Partners Inc.	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income	147,683	254,376	330,972	284,540
Other comprehensive income	2,305	13,407	3,311	11,963
Total comprehensive income	149,988	267,783	334,283	296,503
Comprehensive income attributable to DaVita HealthCare Partners Inc.	149,988	267,783	334,283	296,503
Guarantor Subsidiaries	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income	174,067	195,455	330,339	201,617
Total comprehensive income	174,067	195,455	330,339	201,617
Comprehensive income attributable to DaVita HealthCare Partners Inc.	174,067	195,455	330,339	201,617
Non-Guarantor Subsidiaries	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income	143,943	90,387	241,616	204,872
Total comprehensive income	143,943	90,387	241,616	204,872
Comprehensive income attributable to DaVita HealthCare Partners Inc.	143,943	90,387	241,616	204,872
Consolidating Adjustments	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income	-284,272	-256,860	-509,769	-347,937
Total comprehensive income	-284,272	-256,860	-509,769	-347,937
Less: Comprehensive income attributable to noncontrolling interests	-33,738	-28,982	-62,186	-58,552
Comprehensive income attributable to DaVita HealthCare Partners Inc.	($318,010)	($285,842)	($571,955)	($406,489)

Condensed_Consolidating_Balanc

Condensed Consolidating Balance Sheets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Cash and cash equivalents	$1,420,973	$946,249	$617,904	$533,748
Accounts receivable, net	1,550,252	1,485,163	'	'
Other current assets	1,190,022	1,040,866	'	'
Total current assets	4,161,247	3,472,278	'	'
Property and equipment, net	2,290,844	2,189,411	'	'
Amortizable intangibles, net	2,022,875	2,024,373	'	'
Other long-term assets and investments	196,562	199,841	'	'
Goodwill	9,254,043	9,212,974	'	8,952,750
Total assets	17,925,571	17,098,877	'	'
Current liabilities	2,608,148	2,462,049	'	'
Long-term debt and other long-term liabilities	9,600,356	9,333,987	'	'
Noncontrolling interests subject to put provisions	760,242	697,300	'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	4,785,771	4,432,479	'	'
Noncontrolling interests not subject to put provisions	171,054	173,062	'	'
Total equity	4,956,825	4,605,541	'	'
Total liabilities and equity	17,925,571	17,098,877	'	'
DaVita HealthCare Partners Inc.	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Cash and cash equivalents	1,081,021	602,188	291,231	195,037
Other current assets	83,242	27,910	'	'
Total current assets	1,164,263	630,098	'	'
Property and equipment, net	187,939	177,633	'	'
Amortizable intangibles, net	92,421	77,531	'	'
Investments in subsidiaries	8,784,145	8,231,059	'	'
Intercompany receivables	3,645,401	3,983,214	'	'
Other long-term assets and investments	59,487	61,391	'	'
Total assets	13,933,656	13,160,926	'	'
Current liabilities	496,066	328,875	'	'
Long-term debt and other long-term liabilities	8,157,874	7,948,390	'	'
Noncontrolling interests subject to put provisions	493,945	451,182	'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	4,785,771	4,432,479	'	'
Total equity	4,785,771	4,432,479	'	'
Total liabilities and equity	13,933,656	13,160,926	'	'
Guarantor Subsidiaries	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Cash and cash equivalents	137,229	175,004	123,755	166,107
Accounts receivable, net	953,474	939,543	'	'
Other current assets	971,776	908,010	'	'
Total current assets	2,062,479	2,022,557	'	'
Property and equipment, net	1,394,182	1,377,924	'	'
Amortizable intangibles, net	1,867,978	1,882,685	'	'
Investments in subsidiaries	1,589,418	1,389,558	'	'
Other long-term assets and investments	62,812	67,402	'	'
Goodwill	7,875,336	7,837,421	'	'
Total assets	14,852,205	14,577,547	'	'
Current liabilities	1,744,652	1,774,634	'	'
Intercompany payables	3,115,717	3,421,198	'	'
Long-term debt and other long-term liabilities	1,207,691	1,150,656	'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	8,784,145	8,231,059	'	'
Total equity	8,784,145	8,231,059	'	'
Total liabilities and equity	14,852,205	14,577,547	'	'
Non-Guarantor Subsidiaries	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Cash and cash equivalents	202,723	169,057	202,918	172,604
Accounts receivable, net	596,778	545,620	'	'
Other current assets	135,004	104,946	'	'
Total current assets	934,505	819,623	'	'
Property and equipment, net	708,723	633,854	'	'
Amortizable intangibles, net	62,476	64,157	'	'
Intercompany receivables	545,592	480,993	'	'
Other long-term assets and investments	74,263	71,048	'	'
Goodwill	1,378,707	1,375,553	'	'
Total assets	3,704,266	3,445,228	'	'
Current liabilities	367,430	358,540	'	'
Intercompany payables	1,075,276	1,043,009	'	'
Long-term debt and other long-term liabilities	234,791	234,941	'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	1,589,418	1,389,558	'	'
Noncontrolling interests not subject to put provisions	437,351	419,180	'	'
Total equity	2,026,769	1,808,738	'	'
Total liabilities and equity	3,704,266	3,445,228	'	'
Consolidating Adjustments	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Investments in subsidiaries	-10,373,563	-9,620,617	'	'
Intercompany receivables	-4,190,993	-4,464,207	'	'
Total assets	-14,564,556	-14,084,824	'	'
Intercompany payables	-4,190,993	-4,464,207	'	'
Noncontrolling interests subject to put provisions	266,297	246,118	'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	-10,373,563	-9,620,617	'	'
Noncontrolling interests not subject to put provisions	-266,297	-246,118	'	'
Total equity	-10,639,860	-9,866,735	'	'
Total liabilities and equity	($14,564,556)	($14,084,824)	'	'

Condensed_Consolidating_Statem2

Condensed Consolidating Statements of Cash Flows (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income	$393,158	$343,092
Changes in operating assets and liabilities and non-cash items included in net income	288,340	342,934
Net cash provided by operating activities	681,498	686,026
Cash flows from investing activities:	'	'
Additions of property and equipment, net	-278,593	-258,396
Acquisitions	-98,442	-152,112
Proceeds from asset and business sales	215	64,363
Purchases/proceeds from investment sales and other items	-66,035	-1,742
Net cash provided by (used in) investing activities	-442,855	-347,887
Cash flows from financing activities:	'	'
Long-term debt and related financing costs, net	348,436	-251,368
Other items	-111,788	-2,381
Net cash provided by (used in) financing activities	236,648	-253,749
Effect of exchange rate changes on cash	-567	-234
Net increase (decrease) in cash and cash equivalents	474,724	84,156
Cash and cash equivalents at beginning of period	946,249	533,748
Cash and cash equivalents at end of period	1,420,973	617,904
DaVita HealthCare Partners Inc.	'	'
Cash flows from operating activities:	'	'
Net income	330,972	284,540
Changes in operating assets and liabilities and non-cash items included in net income	-191,299	-271,776
Net cash provided by operating activities	139,673	12,764
Cash flows from investing activities:	'	'
Additions of property and equipment, net	-25,377	-24,213
Proceeds from asset and business sales	'	60,650
Purchases/proceeds from investment sales and other items	-58,496	-2,201
Net cash provided by (used in) investing activities	-83,873	34,236
Cash flows from financing activities:	'	'
Long-term debt and related financing costs, net	353,406	-238,400
Intercompany borrowing	139,052	250,330
Other items	-69,425	37,264
Net cash provided by (used in) financing activities	423,033	49,194
Net increase (decrease) in cash and cash equivalents	478,833	96,194
Cash and cash equivalents at beginning of period	602,188	195,037
Cash and cash equivalents at end of period	1,081,021	291,231
Guarantor Subsidiaries	'	'
Cash flows from operating activities:	'	'
Net income	330,339	201,617
Changes in operating assets and liabilities and non-cash items included in net income	7,007	288,254
Net cash provided by operating activities	337,346	489,871
Cash flows from investing activities:	'	'
Additions of property and equipment, net	-123,519	-131,671
Acquisitions	-97,057	-119,818
Proceeds from asset and business sales	215	3,713
Purchases/proceeds from investment sales and other items	-5,263	359
Net cash provided by (used in) investing activities	-225,624	-247,417
Cash flows from financing activities:	'	'
Long-term debt and related financing costs, net	-7,158	-5,496
Intercompany borrowing	-137,529	-284,739
Other items	-4,810	5,429
Net cash provided by (used in) financing activities	-149,497	-284,806
Net increase (decrease) in cash and cash equivalents	-37,775	-42,352
Cash and cash equivalents at beginning of period	175,004	166,107
Cash and cash equivalents at end of period	137,229	123,755
Non-Guarantor Subsidiaries	'	'
Cash flows from operating activities:	'	'
Net income	241,616	204,872
Changes in operating assets and liabilities and non-cash items included in net income	-37,137	-21,481
Net cash provided by operating activities	204,479	183,391
Cash flows from investing activities:	'	'
Additions of property and equipment, net	-129,697	-102,512
Acquisitions	-1,385	-32,294
Purchases/proceeds from investment sales and other items	-2,276	100
Net cash provided by (used in) investing activities	-133,358	-134,706
Cash flows from financing activities:	'	'
Long-term debt and related financing costs, net	2,188	-7,472
Intercompany borrowing	-1,523	34,409
Other items	-37,553	-45,074
Net cash provided by (used in) financing activities	-36,888	-18,137
Effect of exchange rate changes on cash	-567	-234
Net increase (decrease) in cash and cash equivalents	33,666	30,314
Cash and cash equivalents at beginning of period	169,057	172,604
Cash and cash equivalents at end of period	202,723	202,918
Consolidating Adjustments	'	'
Cash flows from operating activities:	'	'
Net income	-509,769	-347,937
Changes in operating assets and liabilities and non-cash items included in net income	$509,769	$347,937

Supplemental_Data_Condensed_Co

Supplemental Data - Condensed Consolidating Statements of Income (Detail) (USD $)	3 Months Ended			6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Patient service operating revenues	$2,187,249		$2,048,651	$4,301,347		$4,028,524
Less: Provision for uncollectible accounts	-88,052		-72,191	-171,249		-142,248
Net patient service operating revenues	2,099,197		1,976,460	4,130,098		3,886,276
Capitated revenues	799,369		710,074	1,586,934		1,472,689
Other revenues	273,923		185,139	498,233		342,290
Total net operating revenues	3,172,489		2,871,673	6,215,265		5,701,255
Operating expenses	2,688,194		2,349,653	5,289,745		5,012,374
Operating income	484,295		522,020	925,520		688,881
Debt expense, including refinancing charges	-203,680		-108,096	-310,015		-213,913
Other income	1,693		-1,374	3,391		-776
Income tax expense	100,887		129,192	225,738		144,336
Net income	181,421		283,358	393,158		343,092
Minority interests	-33,738		-28,982	-62,186		-58,552
Net income	147,683		254,376	330,972		284,540
Physician Groups	'		'	'		'
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Patient service operating revenues	29,361		'	60,500		'
Less: Provision for uncollectible accounts	-1,979		'	-2,589		'
Net patient service operating revenues	27,382		'	57,911		'
Capitated revenues	368,551		'	734,680		'
Other revenues	2,313		'	2,879		'
Total net operating revenues	398,246		'	795,470		'
Operating expenses	386,281		'	775,799		'
Operating income	11,965		'	19,671		'
Debt expense, including refinancing charges	-3,423		'	-6,618		'
Other income	25		'	33		'
Income tax expense	2,712		'	4,157		'
Net income	5,855		'	8,929		'
Net income	5,855		'	8,929		'
Unrestricted Subsidiaries	'		'	'		'
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Operating expenses	-16		'	236		'
Operating income	16		'	-236		'
Income tax expense	7		'	-94		'
Net income	9		'	-142		'
Net income	9		'	-142		'
Company and Restricted Subsidiaries	'		'	'		'
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Patient service operating revenues	2,157,888	[1]	'	4,240,847	[1]	'
Less: Provision for uncollectible accounts	-86,073	[1]	'	-168,660	[1]	'
Net patient service operating revenues	2,071,815	[1]	'	4,072,187	[1]	'
Capitated revenues	430,818	[1]	'	852,254	[1]	'
Other revenues	271,610	[1]	'	495,354	[1]	'
Total net operating revenues	2,774,243	[1]	'	5,419,795	[1]	'
Operating expenses	2,301,929	[1]	'	4,513,710	[1]	'
Operating income	472,314	[1]	'	906,085	[1]	'
Debt expense, including refinancing charges	-200,257	[1]	'	-303,397	[1]	'
Other income	1,668	[1]	'	3,358	[1]	'
Income tax expense	98,168	[1]	'	221,675	[1]	'
Net income	175,557	[1]	'	384,371	[1]	'
Minority interests	-33,738	[1]	'	-62,186	[1]	'
Net income	$141,819	[1]	'	$322,185	[1]	'
[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Supplemental_Data_Condensed_Co1

Supplemental Data - Condensed Consolidating Statements of Comprehensive Income (Detail) (USD $)	3 Months Ended			6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Net income	$181,421		$283,358	$393,158		$343,092
Other comprehensive income	2,305		13,407	3,311		11,963
Total comprehensive income	183,726		296,765	396,469		355,055
Less: Comprehensive income attributable to noncontrolling interests	-33,738		-28,982	-62,186		-58,552
Comprehensive income attributable to DaVita HealthCare Partners Inc.	149,988		267,783	334,283		296,503
Physician Groups	'		'	'		'
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Net income	5,855		'	8,929		'
Total comprehensive income	5,855		'	8,929		'
Comprehensive income attributable to DaVita HealthCare Partners Inc.	5,855		'	8,929		'
Unrestricted Subsidiaries	'		'	'		'
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Net income	9		'	-142		'
Total comprehensive income	9		'	-142		'
Comprehensive income attributable to DaVita HealthCare Partners Inc.	9		'	-142		'
Company and Restricted Subsidiaries	'		'	'		'
Condensed Financial Statements, Captions [Line Items]	'		'	'		'
Net income	175,557	[1]	'	384,371	[1]	'
Other comprehensive income	2,305	[1]	'	3,311	[1]	'
Total comprehensive income	177,862	[1]	'	387,682	[1]	'
Less: Comprehensive income attributable to noncontrolling interests	-33,738	[1]	'	-62,186	[1]	'
Comprehensive income attributable to DaVita HealthCare Partners Inc.	$144,124	[1]	'	$325,496	[1]	'
[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Supplemental_Data_Condensed_Co2

Supplemental Data - Condensed Consolidating Balance Sheets (Detail) (USD $)	Jun. 30, 2014		Dec. 31, 2013		Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]	'		'		'	'
Cash and cash equivalents	$1,420,973		$946,249		$617,904	$533,748
Accounts receivable, net	1,550,252		1,485,163		'	'
Other current assets	1,190,022		1,040,866		'	'
Total current assets	4,161,247		3,472,278		'	'
Property and equipment, net	2,290,844		2,189,411		'	'
Amortizable intangibles, net	2,022,875		2,024,373		'	'
Other long-term assets	196,562		199,841		'	'
Goodwill	9,254,043		9,212,974		'	8,952,750
Total assets	17,925,571		17,098,877		'	'
Current liabilities	2,608,148		2,462,049		'	'
Long-term debt and other long-term liabilities	9,600,356		9,333,987		'	'
Noncontrolling interests subject to put provisions	760,242		697,300		'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	4,785,771		4,432,479		'	'
Noncontrolling interests not subject to put provisions	171,054		173,062		'	'
Shareholders' equity	4,956,825		4,605,541		'	'
Total liabilities and shareholder's equity	17,925,571		17,098,877		'	'
Physician Groups	'		'		'	'
Condensed Financial Statements, Captions [Line Items]	'		'		'	'
Cash and cash equivalents	117,313		127,309		'	'
Accounts receivable, net	239,428		235,463		'	'
Other current assets	27,776		35,640		'	'
Total current assets	384,517		398,412		'	'
Property and equipment, net	5,006		5,541		'	'
Amortizable intangibles, net	6,794		7,283		'	'
Other long-term assets	69,311		64,013		'	'
Goodwill	9,181		8,981		'	'
Total assets	474,809		484,230		'	'
Current liabilities	175,238		193,079		'	'
Payables to parent	202,448		194,958		'	'
Long-term debt and other long-term liabilities	83,106		94,727		'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	14,017		1,466		'	'
Shareholders' equity	14,017		1,466		'	'
Total liabilities and shareholder's equity	474,809		484,230		'	'
Unrestricted Subsidiaries	'		'		'	'
Condensed Financial Statements, Captions [Line Items]	'		'		'	'
Other long-term assets	3,089		3,325		'	'
Total assets	3,089		3,325		'	'
Payables to parent	3,089		3,325		'	'
Total liabilities and shareholder's equity	3,089		3,325		'	'
Company and Restricted Subsidiaries	'		'		'	'
Condensed Financial Statements, Captions [Line Items]	'		'		'	'
Cash and cash equivalents	1,303,660	[1]	818,940	[1]	'	'
Accounts receivable, net	1,310,824	[1]	1,249,700	[1]	'	'
Other current assets	1,162,246	[1]	1,005,226	[1]	'	'
Total current assets	3,776,730	[1]	3,073,866	[1]	'	'
Property and equipment, net	2,285,838	[1]	2,183,870	[1]	'	'
Amortizable intangibles, net	2,016,081	[1]	2,017,090	[1]	'	'
Other long-term assets	124,162	[1]	132,503	[1]	'	'
Goodwill	9,244,862	[1]	9,203,993	[1]	'	'
Total assets	17,447,673	[1]	16,611,322	[1]	'	'
Current liabilities	2,432,910	[1]	2,268,970	[1]	'	'
Payables to parent	-205,537	[1]	-198,283	[1]	'	'
Long-term debt and other long-term liabilities	9,517,250	[1]	9,239,260	[1]	'	'
Noncontrolling interests subject to put provisions	760,242	[1]	697,300	[1]	'	'
Total DaVita HealthCare Partners Inc. shareholders' equity	4,771,754	[1]	4,431,013	[1]	'	'
Noncontrolling interests not subject to put provisions	171,054	[1]	173,062	[1]	'	'
Shareholders' equity	4,942,808	[1]	4,604,075	[1]	'	'
Total liabilities and shareholder's equity	$17,447,673	[1]	$16,611,322	[1]	'	'
[1]	After the elimination of the unrestricted subsidiaries and the physician groups

Supplemental_Data_Condensed_Co3

Supplemental Data - Condensed Consolidating Statements of Cash Flows (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013
Cash flows from operating activities:	'		'
Net income	$393,158		$343,092
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	288,340		342,934
Net cash provided by (used in) operating activities	681,498		686,026
Cash flows from investing activities:	'		'
Additions of property and equipment	-278,593		-258,396
Acquisitions and divestitures, net	-98,442		'
Proceeds from discontinued operations	215		'
Investments and other items	-66,035		-1,742
Net cash provided by (used in) investing activities	-442,855		-347,887
Cash flows from financing activities:	'		'
Long-term debt	348,436		-251,368
Other items	-111,788		-2,381
Net cash provided by financing activities	236,648		-253,749
Effect of exchange rate changes on cash	-567		-234
Net increase (decrease) in cash	474,724		84,156
Cash and cash equivalents at beginning of period	946,249		533,748
Cash and cash equivalents at end of period	1,420,973		617,904
Physician Groups	'		'
Cash flows from operating activities:	'		'
Net income	8,929		'
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	-27,961		'
Net cash provided by (used in) operating activities	-19,032		'
Cash flows from investing activities:	'		'
Additions of property and equipment	-20		'
Investments and other items	-2,276		'
Net cash provided by (used in) investing activities	-2,296		'
Cash flows from financing activities:	'		'
Intercompany	11,332		'
Net cash provided by financing activities	11,332		'
Net increase (decrease) in cash	-9,996		'
Cash and cash equivalents at beginning of period	127,309		'
Cash and cash equivalents at end of period	117,313		'
Unrestricted Subsidiaries	'		'
Cash flows from operating activities:	'		'
Net income	-142		'
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	142		'
Company and Restricted Subsidiaries	'		'
Cash flows from operating activities:	'		'
Net income	384,371	[1]	'
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	316,159	[1]	'
Net cash provided by (used in) operating activities	700,530	[1]	'
Cash flows from investing activities:	'		'
Additions of property and equipment	-278,573	[1]	'
Acquisitions and divestitures, net	-98,442	[1]	'
Proceeds from discontinued operations	215	[1]	'
Investments and other items	-63,759	[1]	'
Net cash provided by (used in) investing activities	-440,559	[1]	'
Cash flows from financing activities:	'		'
Long-term debt	348,436	[1]	'
Intercompany	-11,332	[1]	'
Other items	-111,788	[1]	'
Net cash provided by financing activities	225,316	[1]	'
Effect of exchange rate changes on cash	-567	[1]	'
Net increase (decrease) in cash	484,720	[1]	'
Cash and cash equivalents at beginning of period	818,940	[1]	'
Cash and cash equivalents at end of period	$1,303,660	[1]	'
[1]	After the elimination of the unrestricted subsidiaries and the physician groups